1
|
Souissi M, Daliphard S, Picard V, Lebigot E, Jardin F, Bobée V. Elevated MCHC reveals a Southeast Asian Ovalocytosis. Am J Hematol 2024; 99:331-332. [PMID: 37966962 DOI: 10.1002/ajh.27157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2023] [Revised: 10/30/2023] [Accepted: 11/02/2023] [Indexed: 11/17/2023]
Affiliation(s)
- Maïssa Souissi
- Department of Biological Hematology, Rouen University Hospital, Rouen, France
| | - Sylvie Daliphard
- Department of Biological Hematology, Rouen University Hospital, Rouen, France
| | - Véronique Picard
- Service d'Hématologie biologique, Hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre, France
- Laboratoire d'Hématologie, Faculté de Pharmacie, Université Paris-Saclay, Orsay, France
| | - Elise Lebigot
- Service de Biochimie-pharmaco-toxicologie, Hôpital Bicêtre, Hopitaux Universitaires Paris-Saclay, Paris-Saclay, France
| | - Fabrice Jardin
- Department of Hematology, Centre Henri Becquerel, Rouen, France
| | - Victor Bobée
- Department of Biological Hematology, Rouen University Hospital, Rouen, France
| |
Collapse
|
2
|
Caulier A, Jankovsky N, Gautier EF, El Nemer W, Guitton C, Ouled-Haddou H, Guillonneau F, Mayeux P, Salnot V, Bruce J, Picard V, Garçon L. Red blood cell proteomics reveal remnant protein biosynthesis and folding pathways in PIEZO1-related hereditary xerocytosis. Front Physiol 2022; 13:960291. [PMID: 36531183 PMCID: PMC9751340 DOI: 10.3389/fphys.2022.960291] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2022] [Accepted: 10/21/2022] [Indexed: 11/25/2023] Open
Abstract
Hereditary xerocytosis is a dominant red cell membrane disorder characterized by an increased leak of potassium from the inside to outside the red blood cell membrane, associated with loss of water leading to red cell dehydration and chronic hemolysis. 90% of cases are related to heterozygous gain of function mutations in PIEZO1, encoding a mechanotransductor that translates a mechanical stimulus into a biological signaling. Data are still required to understand better PIEZO1-HX pathophysiology. Recent studies identified proteomics as an accurate and high-input tool to study erythroid progenitors and circulating red cell physiology. Here, we isolated red blood cells from 5 controls and 5 HX patients carrying an identified and pathogenic PIEZO1 mutation and performed a comparative deep proteomic analysis. A total of 603 proteins were identified among which 56 were differentially expressed (40 over expressed and 16 under expressed) between controls and HX with a homogenous expression profile within each group. We observed relevant modifications in the protein expression profile related to PIEZO1 mutations, identifying two main "knots". The first contained both proteins of the chaperonin containing TCP1 complex involved in the assembly of unfolded proteins, and proteins involved in translation. The second contained proteins involved in ubiquitination. Deregulation of proteins involved in protein biosynthesis was also observed in in vitro-produced reticulocytes after Yoda1 exposure. Thus, our work identifies significant changes in the protein content of PIEZO1-HX erythrocytes, revealing a "PIEZO1 signature" and identifying potentially targetable pathways in this disease characterized by a heterogeneous clinical expression and contra-indication of splenectomy.
Collapse
Affiliation(s)
- Alexis Caulier
- HEMATIM, CURS, Amiens and Laboratoire d’Hématologie, CHU Amiens, UPJV, Amiens, France
| | - Nicolas Jankovsky
- HEMATIM, CURS, Amiens and Laboratoire d’Hématologie, CHU Amiens, UPJV, Amiens, France
| | - Emilie Fleur Gautier
- 3P5 Proteom’IC, Institut Cochin, INSERM, CNRS, Université Paris Cité, Paris, France
- Institut Imagine-INSERM U1163, Necker Hospital, University of Paris, Paris, France
- Laboratoire d’excellence GR-Ex, Paris, France
| | | | - Corinne Guitton
- Laboratoire d’Hématologie et Filière MCGRE, CHU Bicêtre, Le Kremlin-Bicêtre, France
| | - Hakim Ouled-Haddou
- HEMATIM, CURS, Amiens and Laboratoire d’Hématologie, CHU Amiens, UPJV, Amiens, France
| | - François Guillonneau
- 3P5 Proteom’IC, Institut Cochin, INSERM, CNRS, Université Paris Cité, Paris, France
| | - Patrick Mayeux
- 3P5 Proteom’IC, Institut Cochin, INSERM, CNRS, Université Paris Cité, Paris, France
| | - Virginie Salnot
- 3P5 Proteom’IC, Institut Cochin, INSERM, CNRS, Université Paris Cité, Paris, France
| | - Johanna Bruce
- 3P5 Proteom’IC, Institut Cochin, INSERM, CNRS, Université Paris Cité, Paris, France
| | - Véronique Picard
- Laboratoire d’Hématologie et Filière MCGRE, CHU Bicêtre, Le Kremlin-Bicêtre, France
- Laboratoire d’Hématologie, Faculté de Pharmacie, Université Paris Saclay, Amiens, France
| | - Loïc Garçon
- HEMATIM, CURS, Amiens and Laboratoire d’Hématologie, CHU Amiens, UPJV, Amiens, France
- INSERM U1134, INTS, Paris, France
- Laboratoire d’Hématologie et Filière MCGRE, CHU Bicêtre, Le Kremlin-Bicêtre, France
| |
Collapse
|
3
|
Ghesh L, Besnard T, Joubert M, Picard V, Le Vaillant C, Beneteau C. A Gardos channelopathy associated with non-immune hydrops and fetal loss. Clin Genet 2022; 102:543-547. [PMID: 36031591 DOI: 10.1111/cge.14217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Revised: 07/22/2022] [Accepted: 08/11/2022] [Indexed: 12/01/2022]
Abstract
Dehydrated hereditary stomatocytosis (DHS) (MIM#194380) is a rare autosomal dominant disorder of red blood cell permeability, characterized by a partially or fully compensated nonimmune hemolytic anemia. PIEZO1 is the major gene involved with hundreds of families described, some of which present transient perinatal edema of varying severity. A smaller subset of individuals harbors pathogenic variants in KCNN4, sometimes referred as "Gardos channelopathy". Up to now, only six pathogenic variants in KCNN4 have been reported in 13 unrelated families. Unlike PIEZO1-DHS, neither perinatal edema nor fetal loss has ever been observed linked to KCNN4-DHS. We report the first fetal loss due to non-immune hydrops fetalis related to a pathogenic 28 bp deletion (NM_002250.2: c.1109_1119+17del) in KCNN4. This observation underlies the need for very close monitoring of pregnancies when one parent is affected by DHS regardless of genotype (PIEZO1 or KCNN4).
Collapse
Affiliation(s)
- Leïla Ghesh
- CHU de Nantes, Service de Génétique Médicale, Nantes, France.,CHU de Nantes, UF 9321 de Fœtopathologie et Génétique, Nantes, France
| | - Thomas Besnard
- CHU de Nantes, Service de Génétique Médicale, Nantes, France
| | - Madeleine Joubert
- CHU de Nantes, UF 9321 de Fœtopathologie et Génétique, Nantes, France.,CHU de Nantes, Service d'Anatomie et Cytologie Pathologiques, Nantes, France
| | - Véronique Picard
- Laboratoire d'Hématologie, Center Hospitalier Universitaire Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, Paris, France.,Université Paris Saclay, Faculté de Pharmacie, Chatenay Malabry, France
| | - Claudine Le Vaillant
- CHU de Nantes, Service de Gynécologie-obstétrique, diagnostic anténatal, Nantes, France
| | - Claire Beneteau
- CHU de Nantes, Service de Génétique Médicale, Nantes, France.,CHU de Nantes, UF 9321 de Fœtopathologie et Génétique, Nantes, France
| |
Collapse
|
4
|
Jutant EM, Tu L, Thuillet R, Picard V, Guignabert C, Parent F, Sitbon O, Humbert M, Savale L, Huertas A. Erythrocytes are altered in pulmonary arterial hypertension. Eur Respir J 2022; 59:13993003.00506-2022. [PMID: 35595313 DOI: 10.1183/13993003.00506-2022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2021] [Accepted: 03/20/2022] [Indexed: 11/05/2022]
Affiliation(s)
- Etienne-Marie Jutant
- Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Ly Tu
- Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France
| | - Raphaël Thuillet
- Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France
| | - Véronique Picard
- Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.,Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Biological Haematology, Constitutional Hematopoietic Disorders National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Christophe Guignabert
- Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France
| | - Florence Parent
- Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Olivier Sitbon
- Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Marc Humbert
- Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Laurent Savale
- Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Alice Huertas
- Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France .,INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| |
Collapse
|
5
|
Mansour‐Hendili L, Flamarion E, Michel M, Morbieu C, Gameiro C, Sloma I, Badaoui B, Darnige L, Camard M, Lunati‐Rozie A, Aissat A, Tarfi S, Friedrich C, Picard V, Garçon L, Abermil N, Kaltenbach S, Radford‐Weiss I, Kosmider O, Fanen P, Bartolucci P, Godeau B, Galactéros F, Funalot B. Acquired spherocytosis due to somatic ANK1 mutations as a manifestation of clonal hematopoiesis in elderly patients. Am J Hematol 2022; 97:E285-E288. [PMID: 35560067 DOI: 10.1002/ajh.26593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2022] [Revised: 05/02/2022] [Accepted: 05/05/2022] [Indexed: 11/06/2022]
Affiliation(s)
- Lamisse Mansour‐Hendili
- Département de Biochimie‐Biologie Moléculaire, Pharmacologie, Génétique Médicale AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
- Université Paris‐Est Créteil IMRB Equipe Pirenne, Laboratoire d'excellence LABEX GRex Créteil France
| | - Edouard Flamarion
- Service de Médecine Interne Hôpital Européen Georges Pompidou, AP‐HP, Centre‐Université Paris Cité Paris France
| | - Marc Michel
- Service de Médecine Interne AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
- Université Paris‐Est Créteil, INSERM, IMRB Créteil France
| | - Caroline Morbieu
- Service de Médecine Interne AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
- Université Paris‐Est Créteil, INSERM, IMRB Créteil France
| | - Christine Gameiro
- Département de Biochimie‐Biologie Moléculaire, Pharmacologie, Génétique Médicale AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
| | - Ivan Sloma
- Université Paris‐Est Créteil, INSERM, IMRB Créteil France
- Département d'Hématologie et d'Immunologie AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
| | - Bouchra Badaoui
- Département d'Hématologie et d'Immunologie AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
| | - Luc Darnige
- Département d'Hématologie Hôpital Européen Georges Pompidou, AP‐HP, Centre‐Université Paris Cité Paris France
| | - Marion Camard
- Service de Médecine Interne Hôpital Européen Georges Pompidou, AP‐HP, Centre‐Université Paris Cité Paris France
| | - Ariane Lunati‐Rozie
- Département de Biochimie‐Biologie Moléculaire, Pharmacologie, Génétique Médicale AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
- Université Paris‐Est Créteil, INSERM, IMRB Créteil France
| | - Abdelrazak Aissat
- Département de Biochimie‐Biologie Moléculaire, Pharmacologie, Génétique Médicale AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
- Université Paris‐Est Créteil, INSERM, IMRB Créteil France
| | - Sihem Tarfi
- Université Paris‐Est Créteil, INSERM, IMRB Créteil France
- Département d'Hématologie et d'Immunologie AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
| | - Chloé Friedrich
- Laboratoire d'Hématologie Hôpital Cochin, AP‐HP, Centre‐Université Paris Cité Paris France
| | - Véronique Picard
- Département d'Hématologie Biologique Hôpital Bicêtre, AP‐HP, Université Paris Saclay Le Kremlin‐Bicêtre France
| | - Loïc Garçon
- Laboratoire Hématopoïèse et Immunologie (HEMATIM) EA4666 Université Picardie Jules Verne Amiens France
- Service d'Hématologie Biologique Centre Hospitalier Universitaire Amiens France
- Service de Génétique Constitutionnelle Centre Hospitalier Universitaire Amiens France
| | - Nasséra Abermil
- Centre de Recherche Saint‐Antoine Sorbonne Université, Inserm, Hôpital Saint‐Antoine Paris France
- Service d'Hématologie Biologique Hôpital Saint‐Antoine, AP‐HP, Sorbonne Université Paris France
| | - Sophie Kaltenbach
- Service de Cytogénétique Hôpital Necker enfants malades, AP‐HP, Centre‐Université Paris Cité Paris France
| | - Isabelle Radford‐Weiss
- Service de Cytogénétique Hôpital Necker enfants malades, AP‐HP, Centre‐Université Paris Cité Paris France
| | - Olivier Kosmider
- Laboratoire d'Hématologie Hôpital Cochin, AP‐HP, Centre‐Université Paris Cité Paris France
| | - Pascale Fanen
- Département de Biochimie‐Biologie Moléculaire, Pharmacologie, Génétique Médicale AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
- Université Paris‐Est Créteil, INSERM, IMRB Créteil France
| | - Pablo Bartolucci
- Université Paris‐Est Créteil IMRB Equipe Pirenne, Laboratoire d'excellence LABEX GRex Créteil France
- Red Cell Disease Referral Center—UMGGR AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
| | - Bertrand Godeau
- Service de Médecine Interne AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
- Université Paris‐Est Créteil, INSERM, IMRB Créteil France
| | - Frédéric Galactéros
- Université Paris‐Est Créteil IMRB Equipe Pirenne, Laboratoire d'excellence LABEX GRex Créteil France
- Red Cell Disease Referral Center—UMGGR AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
| | - Benoît Funalot
- Département de Biochimie‐Biologie Moléculaire, Pharmacologie, Génétique Médicale AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
- Université Paris‐Est Créteil, INSERM, IMRB Créteil France
| |
Collapse
|
6
|
Gris T, Besançon M, Joncas FH, Picard V, Bergeron A, Fradet Y, Toren P. Targeting the androgen receptor axis to improve response to bladder cancer immunotherapy. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00168-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
7
|
Chappell K, Francou B, Habib C, Huby T, Leoni M, Cottin A, Nadal F, Adnet E, Paoli E, Oliveira C, Verstuyft C, Davit-Spraul A, Gaignard P, Lebigot E, Duclos-Vallee JC, Young J, Kamenicky P, Adams D, Echaniz-Laguna A, Gonzales E, Bouvattier C, Linglart A, Picard V, Bergoin E, Jacquemin E, Guiochon-Mantel A, Proust A, Bouligand J. Galaxy Is a Suitable Bioinformatics Platform for the Molecular Diagnosis of Human Genetic Disorders Using High-Throughput Sequencing Data Analysis. Five Years of Experience in a Clinical Laboratory. Clin Chem 2021; 68:313-321. [PMID: 34871369 DOI: 10.1093/clinchem/hvab220] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2021] [Accepted: 09/13/2021] [Indexed: 12/12/2022]
Abstract
BACKGROUND To date, the usage of Galaxy, an open-source bioinformatics platform, has been reported primarily in research. We report 5 years' experience (2015 to 2020) with Galaxy in our hospital, as part of the "Assistance Publique-Hôpitaux de Paris" (AP-HP), to demonstrate its suitability for high-throughput sequencing (HTS) data analysis in a clinical laboratory setting. METHODS Our Galaxy instance has been running since July 2015 and is used daily to study inherited diseases, cancer, and microbiology. For the molecular diagnosis of hereditary diseases, 6970 patients were analyzed with Galaxy (corresponding to a total of 7029 analyses). RESULTS Using Galaxy, the time to process a batch of 23 samples-equivalent to a targeted DNA sequencing MiSeq run-from raw data to an annotated variant call file was generally less than 2 h for panels between 1 and 500 kb. Over 5 years, we only restarted the server twice for hardware maintenance and did not experience any significant troubles, demonstrating the robustness of our Galaxy installation in conjunction with HTCondor as a job scheduler and a PostgreSQL database. The quality of our targeted exome sequencing method was externally evaluated annually by the European Molecular Genetics Quality Network (EMQN). Sensitivity was mean (SD)% 99 (2)% for single nucleotide variants and 93 (9)% for small insertion-deletions. CONCLUSION Our experience with Galaxy demonstrates it to be a suitable platform for HTS data analysis with vast potential to benefit patient care in a clinical laboratory setting.
Collapse
Affiliation(s)
- Kenneth Chappell
- Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, DMU15, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France.,MOODS Team, CESP, Inserm, Université Paris-Saclay, Faculté de Médecine Paris-Saclay, Le Kremlin Bicêtre, France.,Université Paris-Saclay, Faculté de Médecine, Inserm UMR_1185, Physiologie et Physiopathologie Endocriniennes, Le Kremlin Bicêtre, France
| | - Bruno Francou
- Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, DMU15, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France.,Université Paris-Saclay, Faculté de Médecine, Inserm UMR_1185, Physiologie et Physiopathologie Endocriniennes, Le Kremlin Bicêtre, France.,Plateforme d'Expertises Maladies Rares Paris-Saclay, APHP.Université Paris Saclay, Le Kremlin Bicêtre, France
| | - Christophe Habib
- Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, DMU15, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France.,Plateforme d'Expertises Maladies Rares Paris-Saclay, APHP.Université Paris Saclay, Le Kremlin Bicêtre, France
| | - Thomas Huby
- Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, DMU15, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France
| | - Marco Leoni
- Direction Informatique-Pôle Infrastructures Systèmes et Applications Critiques, Université Paris-Saclay, Orsay, France
| | - Aurélien Cottin
- Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, DMU15, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France.,Agroécologie, AgroSup Dijon, INRAE, Univ. Bourgogne, Univ. Bourgogne Franche-Comté, Dijon, France
| | - Florian Nadal
- Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, DMU15, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France
| | - Eric Adnet
- Direction Informatique, Assistance Publique Hôpitaux de Paris, AP-HP.Université Paris, Saclay, Le Kremlin Bicêtre, France
| | - Eric Paoli
- Direction Informatique, Assistance Publique Hôpitaux de Paris, AP-HP.Université Paris, Saclay, Le Kremlin Bicêtre, France
| | - Christophe Oliveira
- Service de Biochimie, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France
| | - Céline Verstuyft
- Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, DMU15, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France.,MOODS Team, CESP, Inserm, Université Paris-Saclay, Faculté de Médecine Paris-Saclay, Le Kremlin Bicêtre, France.,Plateforme d'Expertises Maladies Rares Paris-Saclay, APHP.Université Paris Saclay, Le Kremlin Bicêtre, France
| | - Anne Davit-Spraul
- Plateforme d'Expertises Maladies Rares Paris-Saclay, APHP.Université Paris Saclay, Le Kremlin Bicêtre, France.,Service de Biochimie, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France
| | - Pauline Gaignard
- Plateforme d'Expertises Maladies Rares Paris-Saclay, APHP.Université Paris Saclay, Le Kremlin Bicêtre, France.,Service de Biochimie, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France
| | - Elise Lebigot
- Plateforme d'Expertises Maladies Rares Paris-Saclay, APHP.Université Paris Saclay, Le Kremlin Bicêtre, France.,Service de Biochimie, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France
| | - Jean-Charles Duclos-Vallee
- Plateforme d'Expertises Maladies Rares Paris-Saclay, APHP.Université Paris Saclay, Le Kremlin Bicêtre, France.,Centre Hépatobiliaire, FHU Hepatinov, AP-HP.Université Paris-Saclay and Inserm Unit UMR 1193 Hôpital Paul Brousse, Villejuif, France
| | - Jacques Young
- Université Paris-Saclay, Faculté de Médecine, Inserm UMR_1185, Physiologie et Physiopathologie Endocriniennes, Le Kremlin Bicêtre, France.,Plateforme d'Expertises Maladies Rares Paris-Saclay, APHP.Université Paris Saclay, Le Kremlin Bicêtre, France.,Service d'Endocrinologie et des Maladies de la Reproduction, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France
| | - Peter Kamenicky
- Université Paris-Saclay, Faculté de Médecine, Inserm UMR_1185, Physiologie et Physiopathologie Endocriniennes, Le Kremlin Bicêtre, France.,Plateforme d'Expertises Maladies Rares Paris-Saclay, APHP.Université Paris Saclay, Le Kremlin Bicêtre, France.,Service d'Endocrinologie et des Maladies de la Reproduction, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France
| | - David Adams
- Plateforme d'Expertises Maladies Rares Paris-Saclay, APHP.Université Paris Saclay, Le Kremlin Bicêtre, France.,Service de Neurologie, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France
| | - Andoni Echaniz-Laguna
- Plateforme d'Expertises Maladies Rares Paris-Saclay, APHP.Université Paris Saclay, Le Kremlin Bicêtre, France.,Service de Neurologie, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France
| | - Emmanuel Gonzales
- Plateforme d'Expertises Maladies Rares Paris-Saclay, APHP.Université Paris Saclay, Le Kremlin Bicêtre, France.,Service d'Hépatologie et de Transplantation Hépatique Pédiatriques, Centre de Référence National de Maladies Rares du Foie, FILFOIE, ERN RARE LIVER, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre and UMR_S 1193, Université Paris-Saclay, Hepatinov, Orsay, France
| | - Claire Bouvattier
- Université Paris-Saclay, Faculté de Médecine, Inserm UMR_1185, Physiologie et Physiopathologie Endocriniennes, Le Kremlin Bicêtre, France.,Plateforme d'Expertises Maladies Rares Paris-Saclay, APHP.Université Paris Saclay, Le Kremlin Bicêtre, France.,Service d'Endocrinologie et Diabéte de l'enfant, DMU SEA, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France
| | - Agnes Linglart
- Université Paris-Saclay, Faculté de Médecine, Inserm UMR_1185, Physiologie et Physiopathologie Endocriniennes, Le Kremlin Bicêtre, France.,Plateforme d'Expertises Maladies Rares Paris-Saclay, APHP.Université Paris Saclay, Le Kremlin Bicêtre, France.,Service d'Endocrinologie et Diabéte de l'enfant, DMU SEA, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France
| | - Véronique Picard
- Plateforme d'Expertises Maladies Rares Paris-Saclay, APHP.Université Paris Saclay, Le Kremlin Bicêtre, France.,Service d'Hématologie, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France
| | - Emilie Bergoin
- Service d'Assurance Qualité, DMU15, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France
| | - Emmanuel Jacquemin
- Plateforme d'Expertises Maladies Rares Paris-Saclay, APHP.Université Paris Saclay, Le Kremlin Bicêtre, France.,Service d'Hépatologie et de Transplantation Hépatique Pédiatriques, Centre de Référence National de Maladies Rares du Foie, FILFOIE, ERN RARE LIVER, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre and UMR_S 1193, Université Paris-Saclay, Hepatinov, Orsay, France
| | - Anne Guiochon-Mantel
- Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, DMU15, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France.,Université Paris-Saclay, Faculté de Médecine, Inserm UMR_1185, Physiologie et Physiopathologie Endocriniennes, Le Kremlin Bicêtre, France.,Plateforme d'Expertises Maladies Rares Paris-Saclay, APHP.Université Paris Saclay, Le Kremlin Bicêtre, France
| | - Alexis Proust
- Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, DMU15, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France
| | - Jérôme Bouligand
- Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, DMU15, AP-HP.Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France.,Université Paris-Saclay, Faculté de Médecine, Inserm UMR_1185, Physiologie et Physiopathologie Endocriniennes, Le Kremlin Bicêtre, France.,Plateforme d'Expertises Maladies Rares Paris-Saclay, APHP.Université Paris Saclay, Le Kremlin Bicêtre, France
| |
Collapse
|
8
|
Yamaguchi Y, Allegrini B, Rapetti-Mauss R, Picard V, Garçon L, Kohl P, Soriani O, Peyronnet R, Guizouarn H. Hereditary Xerocytosis: Differential Behavior of PIEZO1 Mutations in the N-Terminal Extracellular Domain Between Red Blood Cells and HEK Cells. Front Physiol 2021; 12:736585. [PMID: 34737711 PMCID: PMC8562563 DOI: 10.3389/fphys.2021.736585] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2021] [Accepted: 09/02/2021] [Indexed: 01/10/2023] Open
Abstract
Hereditary Xerocytosis, a rare hemolytic anemia, is due to gain of function mutations in PIEZO1, a non-selective cation channel activated by mechanical stress. How these PIEZO1 mutations impair channel function and alter red blood cell (RBC) physiology, is not completely understood. Here, we report the characterization of mutations in the N-terminal part of the protein (V598M, F681S and the double mutation G782S/R808Q), a part of the channel that was subject of many investigations to decipher its role in channel gating. Our data show that the electrophysiological features of these PIEZO1 mutants expressed in HEK293T cells are different from previously characterized PIEZO1 mutations that are located in the pore or at the C-terminal extracellular domain of the protein. Although RBC with PIEZO1 mutations showed a dehydrated phenotype, the activity of V598M, F681S or R808Q in response to stretch was not significantly different from the WT channels. In contrast, the G782S mutant showed larger currents compared to the WT PIEZO1. Interestingly, basal activity of all the mutated channels was not significantly altered at the opposite of what was expected according to the decreased water and cation contents of resting RBC. In addition, the features of mutant PIEZO1 expressed in HEK293 cells do not always correlate with the observation in RBC where PIEZO1 mutations induced a cation leak associated with an increased conductance. Our work emphasizes the role of the membrane environment in PIEZO1 activity and the need to characterize RBC permeability to assess pathogenicity to PIEZO1 mutants associated with erythrocyte diseases.
Collapse
Affiliation(s)
- Yohei Yamaguchi
- Institute for Experimental Cardiovascular Medicine, University Heart Center Freiburg, Bad Krozingen, Germany.,Medical Center and Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany
| | - Benoit Allegrini
- Université Côte d'Azur, CNRS, INSERM, Institut de Biologie Valrose, Nice, France
| | | | - Véronique Picard
- Université Paris Sud-Paris Saclay, Faculté de Pharmacie, Service d'Hématologie Biologique, Hôpital Bicêtre, APHP, Le Kremlin-Bicêtre, France
| | - Loïc Garçon
- Université Picardie Jules Verne, EA 4666, Service d'Hématologie Biologique, CHU, Amiens, France
| | - Peter Kohl
- Institute for Experimental Cardiovascular Medicine, University Heart Center Freiburg, Bad Krozingen, Germany.,Medical Center and Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.,CIBSS - Centre for Integrative Biological Signalling Studies, University of Freiburg, Freiburg im Breisgau, Germany
| | - Olivier Soriani
- Université Côte d'Azur, CNRS, INSERM, Institut de Biologie Valrose, Nice, France
| | - Rémi Peyronnet
- Institute for Experimental Cardiovascular Medicine, University Heart Center Freiburg, Bad Krozingen, Germany.,Medical Center and Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany
| | - Hélène Guizouarn
- Université Côte d'Azur, CNRS, INSERM, Institut de Biologie Valrose, Nice, France
| |
Collapse
|
9
|
Mansour-Hendili L, Egee S, Tarfi S, Badaoui B, De Luna G, Noizat C, Aissat A, Gameiro C, Faubert E, Picard V, Moutereau S, Makowski C, Barro C, Garban F, Jebali A, Bartolucci P, Funalot B, Galacteros F. Les anémies hémolytiques constitutionnelles de causes multiples dévoilées par le séquençage haut-débit. Transfus Clin Biol 2021. [DOI: 10.1016/j.tracli.2021.08.126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Vignes S, Kaltenbach S, Garçon L, Arrivé L, Asnafi V, Guitton C, Bouligand J, Delarue A, Picard V. PIEZO1-gene gain-of-function mutations with lower limb lymphedema onset in an adult: Clinical, scintigraphic, and noncontrast magnetic resonance lymphography findings. Am J Med Genet A 2021; 188:243-248. [PMID: 34477311 DOI: 10.1002/ajmg.a.62476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2020] [Revised: 07/16/2021] [Accepted: 08/05/2021] [Indexed: 11/10/2022]
Abstract
Primary lymphedema, a rare disease, has a genetic cause in ~40% of patients. Recently, loss-of-function mutations in PIEZO1, which encodes the mechanotransducer protein PIEZO1, were described as causing primary lymphedema, when gain-of-function PIEZO1 mutations were attributed to dehydrated hereditary stomatocytosis type-1 (DHS), a dominant red cell hemolytic disorder, with ~20% of patients having perinatal edema. Lymphedema was diagnosed in a 36-year-old man from a three-generation DHS family, with a PIEZO1-allele harboring 3 missense mutations in cis. Four affected family members had severe fetal and neonatal edema, most severe in the proband, whose generalized edema with prevailing ascites resolved after 8 months. Our patient's intermittent lower limb-lymphedema episodes during hot periods appeared at puberty; they became persistent and bilateral at age 32. Clinical Stemmer's sign confirmed lymphedema. Lower leg lymphoscintigraphy showed substantial dermal backflow in both calves, predominantly on the right. Noncontrast magnetic resonance lymphography showed bilateral lower limb lymphedema, dilated dysplastic lymphatic iliac, and inguinal trunks. Exome-sequencing analysis identified no additional pathogenic variation in primary lymphedema-associated genes. This is the first description of well-documented lymphedema in an adult with PIEZO1-DHS. The pathophysiology of PIEZO1-associated primary lymphedema is poorly understood. Whether it infers overlapping phenotypes or different mechanisms of gain- and loss-of-function PIEZO1 mutations deserves further investigation.
Collapse
Affiliation(s)
- Stéphane Vignes
- Unité de Lymphologie, Centre de Référence des Maladies Vasculaires Rares, Hôpital Cognacq-Jay, Paris, France
| | - Sophie Kaltenbach
- Université de Paris (Descartes), Institut Necker-Enfants Malades, Institut National de la Santé et de la Recherche Médicale U1151, Paris, France.,Laboratoire d'Onco-Hématologie, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Necker Enfants-Malades, Paris, France
| | - Loïc Garçon
- Equipe d'Accueil 4666 HEMATIM, Université de Picardie Jules-Verne, Amiens, France.,Département d'Hématologie, Centre Hospitalier Universitaire (CHU) d'Amiens, Amiens, France
| | - Lionel Arrivé
- Service de Radiologie, APHP, CHU Saint-Antoine, Paris, France
| | - Vahid Asnafi
- Université de Paris (Descartes), Institut Necker-Enfants Malades, Institut National de la Santé et de la Recherche Médicale U1151, Paris, France.,Laboratoire d'Onco-Hématologie, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Necker Enfants-Malades, Paris, France
| | - Corinne Guitton
- Service de Pédiatrie, APHP, CHU Bicêtre, Le Kremlin-Bicêtre, France
| | - Jérôme Bouligand
- Département de Génétique, APHP, CHU Bicêtre, Le Kremlin-Bicêtre, France
| | - Audrey Delarue
- Unité de Lymphologie, Centre de Référence des Maladies Vasculaires Rares, Hôpital Cognacq-Jay, Paris, France
| | - Véronique Picard
- Service d'Hématologie Biologique, APHP, CHU Bicêtre, Le Kremlin-Bicêtre, France.,Faculté de Pharmacie, Université Paris-Saclay, Chatenay-Malabry, France
| |
Collapse
|
11
|
Mansour‐Hendili L, Egée S, Monedero‐Alonso D, Bouyer G, Godeau B, Badaoui B, Lunati A, Noizat C, Aissat A, Kiger L, Mekki C, Picard V, Moutereau S, Fanen P, Bartolucci P, Garçon L, Galactéros F, Funalot B. Multiple thrombosis in a patient with Gardos channelopathy and a new KCNN4 mutation. Am J Hematol 2021; 96:E318-E321. [PMID: 34004026 DOI: 10.1002/ajh.26245] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Revised: 05/14/2021] [Accepted: 05/14/2021] [Indexed: 11/10/2022]
Affiliation(s)
- Lamisse Mansour‐Hendili
- Département de Biochimie‐Biologie Moléculaire, Pharmacologie, Génétique Médicale, AP‐HP Hôpitaux Universitaires Henri Mondor 51 Avenue du Maréchal de Lattre de Tassigny Créteil Val‐deMarne France
- IMRB Equipe Pirenne, Laboratoire d'excellence LABEX GRex Université Paris Est Créteil 61 Avenue du Général de Gaulle Créteil Val‐de‐Marne 94000 France
| | - Stéphane Egée
- CNRS, Integrative Biology of Marine Models Sorbonne Université Place Georges Teissier Roscoff Finistère 29680 France
- Laboratoire d'Excellence GR‐Ex Laboratoire d'Excellence GR‐Ex 24, Boulevard du Montparnasse Paris ile‐de‐France 75015 France
| | - David Monedero‐Alonso
- CNRS, Integrative Biology of Marine Models Sorbonne Université Place Georges Teissier Roscoff Finistère 29680 France
- Laboratoire d'Excellence GR‐Ex Laboratoire d'Excellence GR‐Ex 24, Boulevard du Montparnasse Paris ile‐de‐France 75015 France
| | - Guillaume Bouyer
- CNRS, Integrative Biology of Marine Models Sorbonne Université Place Georges Teissier Roscoff Finistère 29680 France
- Laboratoire d'Excellence GR‐Ex Laboratoire d'Excellence GR‐Ex 24, Boulevard du Montparnasse Paris ile‐de‐France 75015 France
| | - Bertrand Godeau
- Département de médecine interne AP‐HP, Hôpitaux Universitaires Henri Mondor 51 avenue du MAréchal de Lattre de Tassigny Créteil Val‐de‐Marne 94010 France
- INSERM, IMRB Université Paris Est Créteil 61 avenue du Général de Gaulle Créteil Val‐de‐Marne 94000 France
| | - Bouchra Badaoui
- Département d'hématologie et d'immunologie AP‐HP, Hôpitaux Universitaires Henri Mondor 51 avenue du Maréchal de Lattre de Tassigny Créteil Val‐de‐Marne 94010 France
| | - Ariane Lunati
- Département de Biochimie‐Biologie Moléculaire, Pharmacologie, Génétique Médicale, AP‐HP Hôpitaux Universitaires Henri Mondor 51 Avenue du Maréchal de Lattre de Tassigny Créteil Val‐deMarne France
- INSERM, IMRB Université Paris Est Créteil 61 avenue du Général de Gaulle Créteil Val‐de‐Marne 94000 France
| | - Clara Noizat
- Département de Biochimie‐Biologie Moléculaire, Pharmacologie, Génétique Médicale, AP‐HP Hôpitaux Universitaires Henri Mondor 51 Avenue du Maréchal de Lattre de Tassigny Créteil Val‐deMarne France
| | - Abdelrazak Aissat
- Département de Biochimie‐Biologie Moléculaire, Pharmacologie, Génétique Médicale, AP‐HP Hôpitaux Universitaires Henri Mondor 51 Avenue du Maréchal de Lattre de Tassigny Créteil Val‐deMarne France
- INSERM, IMRB Université Paris Est Créteil 61 avenue du Général de Gaulle Créteil Val‐de‐Marne 94000 France
| | - Laurent Kiger
- IMRB Equipe Pirenne, Laboratoire d'excellence LABEX GRex Université Paris Est Créteil 61 Avenue du Général de Gaulle Créteil Val‐de‐Marne 94000 France
| | - Chadia Mekki
- Département de Biochimie‐Biologie Moléculaire, Pharmacologie, Génétique Médicale, AP‐HP Hôpitaux Universitaires Henri Mondor 51 Avenue du Maréchal de Lattre de Tassigny Créteil Val‐deMarne France
| | - Véronique Picard
- Département d'hématologie biologique AP‐HP, Hôpital Bicêtre 78 Rue du Général Leclerc Le Kremlin‐Bicêtre Val‐de‐MArne 94270 France
| | - Stéphane Moutereau
- Département de Biochimie‐Biologie Moléculaire, Pharmacologie, Génétique Médicale, AP‐HP Hôpitaux Universitaires Henri Mondor 51 Avenue du Maréchal de Lattre de Tassigny Créteil Val‐deMarne France
- IMRB Equipe Pirenne, Laboratoire d'excellence LABEX GRex Université Paris Est Créteil 61 Avenue du Général de Gaulle Créteil Val‐de‐Marne 94000 France
| | - Pascale Fanen
- Département de Biochimie‐Biologie Moléculaire, Pharmacologie, Génétique Médicale, AP‐HP Hôpitaux Universitaires Henri Mondor 51 Avenue du Maréchal de Lattre de Tassigny Créteil Val‐deMarne France
- INSERM, IMRB Université Paris Est Créteil 61 avenue du Général de Gaulle Créteil Val‐de‐Marne 94000 France
| | - Pablo Bartolucci
- IMRB Equipe Pirenne, Laboratoire d'excellence LABEX GRex Université Paris Est Créteil 61 Avenue du Général de Gaulle Créteil Val‐de‐Marne 94000 France
- Red Cell Disease Referral Center – UMGGR AP‐HP, Hôpitaux Universitaires Henri Mondor 51 avenue du Maréchal de Lattre de Tassigny Créteil Val‐de‐Marne 94010 France
| | - Loïc Garçon
- Laboratoire Hématopoïèse et Immunologie (HEMATIM) EA4666 Université Picardie Jules Verne 51 Boulevard de Châteaudun Amiens Hauts‐de‐France 80000 France
- Service d'Hématologie Biologique CHU d'Amiens 1 rond‐point du Professeur Christian Cabrol Amiens Hauts‐de‐France 80000 France
- Service de Génétique Constitutionnelle CHU d'Amiens 1 rond‐point du Professeur Christian Cabrol Amiens Hauts‐de‐France 80000 France
| | - Frédéric Galactéros
- IMRB Equipe Pirenne, Laboratoire d'excellence LABEX GRex Université Paris Est Créteil 61 Avenue du Général de Gaulle Créteil Val‐de‐Marne 94000 France
- Red Cell Disease Referral Center – UMGGR AP‐HP, Hôpitaux Universitaires Henri Mondor 51 avenue du Maréchal de Lattre de Tassigny Créteil Val‐de‐Marne 94010 France
| | - Benoît Funalot
- Département de Biochimie‐Biologie Moléculaire, Pharmacologie, Génétique Médicale, AP‐HP Hôpitaux Universitaires Henri Mondor 51 Avenue du Maréchal de Lattre de Tassigny Créteil Val‐deMarne France
- INSERM, IMRB Université Paris Est Créteil 61 avenue du Général de Gaulle Créteil Val‐de‐Marne 94000 France
| |
Collapse
|
12
|
Jankovsky N, Caulier A, Demagny J, Guitton C, Djordjevic S, Lebon D, Ouled‐Haddou H, Picard V, Garçon L. Recent advances in the pathophysiology of PIEZO1-related hereditary xerocytosis. Am J Hematol 2021; 96:1017-1026. [PMID: 33848364 DOI: 10.1002/ajh.26192] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2021] [Revised: 04/09/2021] [Accepted: 04/12/2021] [Indexed: 02/06/2023]
Abstract
Hereditary xerocytosis is a rare red blood cell disease related to gain-of-function mutations in the FAM38A gene, encoding PIEZO1, in 90% of cases; PIEZO1 is a broadly expressed mechano-transducer that plays a major role in many cell systems and tissues that respond to mechanical stress. In erythrocytes, PIEZO1 adapts the intracellular ionic content and cell hydration status to the mechanical constraints induced by the environment. Until recently, the pathophysiology of hereditary xerocytosis was mainly believed to be based on the "PIEZO1-Gardos channel axis" in erythrocytes, according to which PIEZO1-activating mutations induce a calcium influx that secondarily activates the Gardos channel, leading to potassium and water efflux and subsequently to red blood cell dehydration. However, recent studies have demonstrated additional roles for PIEZO1 during early erythropoiesis and reticulocyte maturation, as well as roles in other tissues and cells such as lymphatic vessels, hepatocytes, macrophages and platelets that may affect the pathophysiology of the disease. These findings, presented and discussed in this review, broaden our understanding of hereditary xerocytosis beyond that of primarily being a red blood cell disease and identify potential therapeutic targets.
Collapse
Affiliation(s)
- Nicolas Jankovsky
- UR4666 HEMATIM Université Picardie Jules Verne Amiens France
- Service d'Hématologie Clinique, CHU Amiens‐Picardie Amiens France
| | - Alexis Caulier
- UR4666 HEMATIM Université Picardie Jules Verne Amiens France
- Service d'Hématologie Clinique, CHU Amiens‐Picardie Amiens France
| | - Julien Demagny
- UR4666 HEMATIM Université Picardie Jules Verne Amiens France
- Service d'Hématologie Biologique, CHU Amiens‐Picardie Amiens France
| | - Corinne Guitton
- Service de Pédiatrie Générale, CHU Bicêtre Le Kremlin‐Bicêtre France
- Centre de référence des maladies constitutionnelles du globule rouge et de l'érythropoïèse (Filière MCGRE) Créteil France
| | | | - Delphine Lebon
- UR4666 HEMATIM Université Picardie Jules Verne Amiens France
- Service d'Hématologie Clinique, CHU Amiens‐Picardie Amiens France
| | | | - Véronique Picard
- Centre de référence des maladies constitutionnelles du globule rouge et de l'érythropoïèse (Filière MCGRE) Créteil France
- Service d'Hématologie Biologique, CHU Bicêtre Le Kremlin‐Bicêtre France
- Faculté de Pharmacie Université Paris Saclay Châtenay‐Malabry France
| | - Loïc Garçon
- UR4666 HEMATIM Université Picardie Jules Verne Amiens France
- Service d'Hématologie Biologique, CHU Amiens‐Picardie Amiens France
- Centre de référence des maladies constitutionnelles du globule rouge et de l'érythropoïèse (Filière MCGRE) Créteil France
| |
Collapse
|
13
|
Mansour A, Decouture B, Roussel M, Lefevre C, Skreko L, Picard V, Ouattara A, Bachelot-Loza C, Gaussem P, Nesseler N, Gouin-Thibault I. Combined Platelet and Erythrocyte Salvage: Evaluation of a New Filtration-based Autotransfusion Device. Anesthesiology 2021; 135:246-257. [PMID: 33984126 DOI: 10.1097/aln.0000000000003820] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND The SAME device (i-SEP, France) is an innovative filtration-based autotransfusion device able to salvage and wash both red blood cells and platelets. This study evaluated the device performances using human whole blood with the hypothesis that the device will be able to salvage platelets while achieving a erythrocyte yield of 80% and removal ratios of 90% for heparin and 80% for major plasma proteins without inducing signification activation of salvaged cells. METHODS Thirty healthy human whole blood units (median volume, 478 ml) were diluted, heparinized, and processed by the device in two consecutive treatment cycles. Samples from the collection reservoir and the concentrated blood were analyzed. Complete blood count was performed to measure blood cell recovery rates. Flow cytometry evaluated the activation state and function of platelets and leukocytes. Heparin and plasma proteins were measured to assess washing performance. RESULTS The global erythrocyte yield was 88.1% (84.1 to 91.1%; median [25th to 75th]) with posttreatment hematocrits of 48.9% (44.8 to 51.4%) and 51.4% (48.4 to 53.2%) for the first and second cycles, respectively. Ektacytometry did not show evidence of erythrocyte alteration. Platelet recovery was 36.8% (26.3 to 43.4%), with posttreatment counts of 88 × 109/l (73 to 101 × 109/l) and 115 × 109/l (95 to 135 × 109/l) for the first and second cycles, respectively. Recovered platelets showed a low basal P-selectin expression at 10.8% (8.1 to 15.2%) and a strong response to thrombin-activating peptide. Leukocyte yield was 93.0% (90.1 to 95.7%) with no activation or cell death. Global removal ratios were 98.3% (97.8 to 98.9%), 98.2% (96.9 to 98.8%), and 88.3% (86.6 to 90.7%) for heparin, albumin, and fibrinogen, respectively. The processing times were 4.4 min (4.2 to 4.6 min) and 4.4 min (4.2 to 4.7 min) for the first and second cycles, respectively. CONCLUSIONS This study demonstrated the performance of the SAME device. Platelets and red blood cells were salvaged without significant impact on cell integrity and function. In the meantime, leukocytes were not activated, and the washing quality of the device prevented reinfusion of high concentrations of heparin and plasma proteins. EDITOR’S PERSPECTIVE
Collapse
|
14
|
Pérès L, Monedero Alonso D, Nudel M, Figeac M, Bruge J, Sebda S, Picard V, El Nemer W, Preudhomme C, Rose C, Egée S, Bouyer G. Characterisation of Asp669Tyr Piezo1 cation channel activity in red blood cells: an unexpected phenotype. Br J Haematol 2021; 194:e51-e55. [PMID: 33973227 DOI: 10.1111/bjh.17467] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Affiliation(s)
- Laurent Pérès
- Sorbonne Université, CNRS, UMR8227, Station Biologique de Roscoff, Roscoff, France.,Laboratoire d'Excellence GR-Ex, Paris, France
| | - David Monedero Alonso
- Sorbonne Université, CNRS, UMR8227, Station Biologique de Roscoff, Roscoff, France.,Laboratoire d'Excellence GR-Ex, Paris, France
| | - Morgane Nudel
- Hôpital Saint Vincent de Paul, Université Catholique, Lille, France
| | - Martin Figeac
- Univ-Lille, Plate-forme de Génomique Fonctionnelle et Structurale, Lille, France.,CHU Lille, cellule bioinformatique, plateau commun de séquençage, Lille, France
| | - Judith Bruge
- Hôpital Saint Vincent de Paul, Université Catholique, Lille, France
| | - Shéhérazade Sebda
- Univ-Lille, Plate-forme de Génomique Fonctionnelle et Structurale, Lille, France
| | | | - Wassim El Nemer
- Inserm, UMR_S 1134, Institut National de la Transfusion Sanguine INTS, Paris, France.,Laboratoire d'Excellence GR-Ex, Paris, France
| | - Claude Preudhomme
- Univ-Lille, Plate-forme de Génomique Fonctionnelle et Structurale, Lille, France
| | - Christian Rose
- Hôpital Saint Vincent de Paul, Université Catholique, Lille, France
| | - Stéphane Egée
- Sorbonne Université, CNRS, UMR8227, Station Biologique de Roscoff, Roscoff, France.,Laboratoire d'Excellence GR-Ex, Paris, France
| | - Guillaume Bouyer
- Sorbonne Université, CNRS, UMR8227, Station Biologique de Roscoff, Roscoff, France.,Laboratoire d'Excellence GR-Ex, Paris, France
| |
Collapse
|
15
|
Picard V, Guitton C, Mansour-Hendili L, Jondeau B, Bendélac L, Denguir M, Demagny J, Proulle V, Galactéros F, Garçon L. Rapid Gardos Hereditary Xerocytosis Diagnosis in 8 Families Using Reticulocyte Indices. Front Physiol 2021; 11:602109. [PMID: 33519508 PMCID: PMC7841495 DOI: 10.3389/fphys.2020.602109] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2020] [Accepted: 12/11/2020] [Indexed: 11/30/2022] Open
Abstract
Gardos channelopathy (Gardos-HX) or type 2 stomatocytosis/xerocytosis is a hereditary hemolytic anemia due to mutations in the KCNN4 gene. It is rarer than inherited type 1 xerocytosis due to PIEZO1 mutations (Piezo1-HX) and its diagnosis is difficult given the absence of a specific clinical or biological phenotype. We report here that this diagnosis can be sped up using red blood cell (RBC) indices performed on an ADVIA 2120 (Siemens®) analyzer, which measures reticulocyte mean corpuscular volume (rMCV) and mean corpuscular hemoglobin concentration (rMCHC). We studied reticulocyte indices in 3 new and 12 described patients (8 families) with Gardos-HX, 11 subjects presented the recurrent p.Arg352His mutation, 4 cases (two families) carried a private KCNN4 mutation. They were compared to 79 described patients (49 families) with Piezo1-HX. Surprisingly, in Gardos-HX cases, rMCV revealed to be smaller than MCV and rMCHC higher than MCHC, in contrast with normal or Piezo1-HX RBC. Consequently, ΔMCV (rMCV-MCV) was −0.9 ± 5 fL vs. 19.8 ± 3 fL (p < 0.001) in Gardos compared with Piezo1-HX and ΔMCHC (rMCHC-MCHC) was 18.7 ± 13 vs. −50 ± 8.7 g/L (p < 0.001). A threshold of 8.6 fL for ΔMCV and −5.5 g/L for ΔMCHC could discriminate between Gardos and Piezo1-HX with 100% sensitivity and specificity, regardless of age, mutation or splenectomy status. Consequently, we showed that reticulocytes indices are useful to suggest Gardos-HX on blood count results, allowing to rapidly target these patients for gene analysis. In addition, these parameters may prove useful as a ‘functional tool’ in interpreting new KCNN4 variants.
Collapse
Affiliation(s)
- Véronique Picard
- Service d'Hématologie Biologique, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Hôpitaux Universitaires Paris-Saclay, Le Kremlin-Bicêtre, France.,Faculté de Pharmacie, Université Paris-Saclay, Châtenay-Malabry, France
| | - Corinne Guitton
- Service de Pédiatrie Générale, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Filière MCGRE, Hôpitaux Universitaires Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Lamisse Mansour-Hendili
- Department of Molecular Genetics, Assistance Publique-Hôpitaux de Paris, Henri Mondor University Hospital, Créteil, France
| | - Bernard Jondeau
- Service d'Hématologie Biologique, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Hôpitaux Universitaires Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Laurence Bendélac
- Service d'Hématologie Biologique, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Hôpitaux Universitaires Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Maha Denguir
- Service de Biochimie, Assistance Publique-Hôpitaux de Paris, Bicêtre Hospital, Le Kremlin-Bicêtre, France
| | - Julien Demagny
- Service d'Hématologie Biologique, CHU Amiens, EA 4666 HEMATIM-UPJV, Amiens, France
| | - Valérie Proulle
- Service d'Hématologie Biologique, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Hôpitaux Universitaires Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Frédéric Galactéros
- Centre de Référence des Syndromes Drépanocytaires Majeurs, Hôpital Henri-Mondor, AP-HP, Créteil, France
| | - Loic Garçon
- Service d'Hématologie Biologique, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Hôpitaux Universitaires Paris-Saclay, Le Kremlin-Bicêtre, France.,Service d'Hématologie Biologique, CHU Amiens, EA 4666 HEMATIM-UPJV, Amiens, France
| |
Collapse
|
16
|
Mansour-Hendili L, Aissat A, Badaoui B, Sakka M, Gameiro C, Ortonne V, Wagner-Ballon O, Pissard S, Picard V, Ghazal K, Bahuau M, Guitton C, Mansour Z, Duplan M, Petit A, Costedoat-Chalumeau N, Michel M, Bartolucci P, Moutereau S, Funalot B, Galactéros F. Exome sequencing for diagnosis of congenital hemolytic anemia. Orphanet J Rare Dis 2020; 15:180. [PMID: 32641076 PMCID: PMC7341591 DOI: 10.1186/s13023-020-01425-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2020] [Accepted: 05/27/2020] [Indexed: 02/07/2023] Open
Abstract
Background Congenital hemolytic anemia constitutes a heterogeneous group of rare genetic disorders of red blood cells. Diagnosis is based on clinical data, family history and phenotypic testing, genetic analyses being usually performed as a late step. In this study, we explored 40 patients with congenital hemolytic anemia by whole exome sequencing: 20 patients with hereditary spherocytosis and 20 patients with unexplained hemolysis. Results A probable genetic cause of disease was identified in 82.5% of the patients (33/40): 100% of those with suspected hereditary spherocytosis (20/20) and 65% of those with unexplained hemolysis (13/20). We found that several patients carried genetic variations in more than one gene (3/20 in the hereditary spherocytosis group, 6/13 fully elucidated patients in the unexplained hemolysis group), giving a more accurate picture of the genetic complexity of congenital hemolytic anemia. In addition, whole exome sequencing allowed us to identify genetic variants in non-congenital hemolytic anemia genes that explained part of the phenotype in 3 patients. Conclusion The rapid development of next generation sequencing has rendered the genetic study of these diseases much easier and cheaper. Whole exome sequencing in congenital hemolytic anemia could provide a more precise and quicker diagnosis, improve patients’ healthcare and probably has to be democratized notably for complex cases.
Collapse
Affiliation(s)
- Lamisse Mansour-Hendili
- Département de Biochimie-Biologie Moléculaire, Pharmacologie, Génétique Médicale, AP-HP, Hôpitaux Universitaires Henri Mondor, F-94010, Creteil, France. .,Univ Paris Est Creteil, INSERM, IMRB, F-94010, Creteil, France.
| | - Abdelrazak Aissat
- Département de Biochimie-Biologie Moléculaire, Pharmacologie, Génétique Médicale, AP-HP, Hôpitaux Universitaires Henri Mondor, F-94010, Creteil, France.,Univ Paris Est Creteil, INSERM, IMRB, F-94010, Creteil, France
| | - Bouchra Badaoui
- Département d'hématologie et d'immunologie, AP-HP, Hôpitaux Universitaires Henri Mondor, F-94010, Creteil, France
| | - Mehdi Sakka
- Département de Biochimie-Biologie Moléculaire, Pharmacologie, Génétique Médicale, AP-HP, Hôpitaux Universitaires Henri Mondor, F-94010, Creteil, France.,Univ Paris Est Creteil, INSERM, IMRB, F-94010, Creteil, France
| | - Christine Gameiro
- Département de Biochimie-Biologie Moléculaire, Pharmacologie, Génétique Médicale, AP-HP, Hôpitaux Universitaires Henri Mondor, F-94010, Creteil, France
| | - Valérie Ortonne
- Département de Biochimie-Biologie Moléculaire, Pharmacologie, Génétique Médicale, AP-HP, Hôpitaux Universitaires Henri Mondor, F-94010, Creteil, France
| | - Orianne Wagner-Ballon
- Univ Paris Est Creteil, INSERM, IMRB, F-94010, Creteil, France.,Département d'hématologie et d'immunologie, AP-HP, Hôpitaux Universitaires Henri Mondor, F-94010, Creteil, France
| | - Serge Pissard
- Département de Biochimie-Biologie Moléculaire, Pharmacologie, Génétique Médicale, AP-HP, Hôpitaux Universitaires Henri Mondor, F-94010, Creteil, France.,Univ Paris Est Creteil, INSERM, IMRB, F-94010, Creteil, France
| | - Véronique Picard
- Département d'hématologie, AP-HP, Hôpital Bicêtre, F-94270, Le Kremlin-Bicêtre, France
| | - Khaldoun Ghazal
- Département de Biochimie, AP-HP, Hôpital Bicêtre, F-94270, Le Kremlin-Bicêtre, France
| | - Michel Bahuau
- Département de Biochimie-Biologie Moléculaire, Pharmacologie, Génétique Médicale, AP-HP, Hôpitaux Universitaires Henri Mondor, F-94010, Creteil, France
| | - Corinne Guitton
- Département d'hématologie pédiatrique, AP-HP, Hôpital Bicêtre, F-94270, Le Kremlin-Bicêtre, France
| | - Ziad Mansour
- Clinique ADASSA, Maternité, F-67000, Strasbourg, France
| | - Mylène Duplan
- Département d'onco-hématologie pédiatrique, CHU d'Angers, 4 Rue Larrey, 49100, Angers, France
| | - Arnaud Petit
- Département d'onco-hématologie pédiatrique, AP-HP, Hôpital Armand Trousseau, F-75012, Paris, France
| | | | - Marc Michel
- Univ Paris Est Creteil, INSERM, IMRB, F-94010, Creteil, France.,Département de médecine interne, AP-HP, Hôpitaux Universitaires Henri Mondor, F-94010, Creteil, France
| | - Pablo Bartolucci
- Univ Paris Est Creteil, INSERM, IMRB, F-94010, Creteil, France.,Département de médecine interne, AP-HP, Hôpitaux Universitaires Henri Mondor, F-94010, Creteil, France.,Unité des maladies génétiques du globule rouge (UMGGR), AP-HP, Hôpitaux Universitaires Henri Mondor, F-94010, Creteil, France
| | - Stéphane Moutereau
- Département de Biochimie-Biologie Moléculaire, Pharmacologie, Génétique Médicale, AP-HP, Hôpitaux Universitaires Henri Mondor, F-94010, Creteil, France.,Univ Paris Est Creteil, INSERM, IMRB, F-94010, Creteil, France
| | - Benoît Funalot
- Département de Biochimie-Biologie Moléculaire, Pharmacologie, Génétique Médicale, AP-HP, Hôpitaux Universitaires Henri Mondor, F-94010, Creteil, France.,Univ Paris Est Creteil, INSERM, IMRB, F-94010, Creteil, France
| | - Frédéric Galactéros
- Univ Paris Est Creteil, INSERM, IMRB, F-94010, Creteil, France.,Département de médecine interne, AP-HP, Hôpitaux Universitaires Henri Mondor, F-94010, Creteil, France.,Unité des maladies génétiques du globule rouge (UMGGR), AP-HP, Hôpitaux Universitaires Henri Mondor, F-94010, Creteil, France
| |
Collapse
|
17
|
Gérard D, Bourin S, Phulpin A, Picard V, Steschenko D, Perrin J. Previously misdiagnosed red cell membrane disorder and familial consequences. Br J Haematol 2020; 190:810. [PMID: 32510597 DOI: 10.1111/bjh.16803] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Delphine Gérard
- Service d'hématologie biologique, CHRU Nancy, Nancy, France.,Université de Lorraine, Inserm, DCAC, Nancy, France
| | - Sophie Bourin
- Service d'hématologie biologique, CHRU Nancy, Nancy, France
| | - Aurélie Phulpin
- Service d'oncohématologie pédiatrique, CHRU Nancy, Nancy, France
| | - Véronique Picard
- Laboratoire d'Hématologie, CHU Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, France
| | | | - Julien Perrin
- Service d'hématologie biologique, CHRU Nancy, Nancy, France.,Université de Lorraine, Inserm, DCAC, Nancy, France
| |
Collapse
|
18
|
Caulier A, Jankovsky N, Demont Y, Ouled-Haddou H, Demagny J, Guitton C, Merlusca L, Lebon D, Vong P, Aubry A, Lahary A, Rose C, Gréaume S, Cardon E, Platon J, Ouadid-Ahidouch H, Rochette J, Marolleau JP, Picard V, Garçon L. PIEZO1 activation delays erythroid differentiation of normal and hereditary xerocytosis-derived human progenitor cells. Haematologica 2019; 105:610-622. [PMID: 31413092 PMCID: PMC7049340 DOI: 10.3324/haematol.2019.218503] [Citation(s) in RCA: 41] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2019] [Accepted: 08/09/2019] [Indexed: 12/21/2022] Open
Abstract
Hereditary xerocytosis is a dominantly inherited red cell membrane disorder caused in most cases by gain-of-function mutations in PIEZO1, encoding a mechanosensitive ion channel that translates a mechanic stimulus into calcium influx. We found that PIEZO1 was expressed early in erythroid progenitor cells, and investigated whether it could be involved in erythropoiesis, besides having a role in the homeostasis of mature red cell hydration. In UT7 cells, chemical PIEZO1 activation using YODA1 repressed glycophorin A expression by 75%. This effect was PIEZO1-dependent since it was reverted using specific short hairpin-RNA knockdown. The effect of PIEZO1 activation was confirmed in human primary progenitor cells, maintaining cells at an immature stage for longer and modifying the transcriptional balance in favor of genes associated with early erythropoiesis, as shown by a high GATA2/GATA1 ratio and decreased α/β-globin expression. The cell proliferation rate was also reduced, with accumulation of cells in G0/G1 of the cell cycle. The PIEZO1-mediated effect on UT7 cells required calcium-dependent activation of the NFAT and ERK1/2 pathways. In primary erythroid cells, PIEZO1 activation synergized with erythropoietin to activate STAT5 and ERK, indicating that it may modulate signaling pathways downstream of erythropoietin receptor activation. Finally, we studied the in-vitro erythroid differentiation of primary cells obtained from 14 PIEZO1-mutated patients, from 11 families, carrying ten different mutations. We observed a delay in erythroid differentiation in all cases, ranging from mild (n=3) to marked (n=8). Overall, these data demonstrate a role for PIEZO1 during erythropoiesis, since activation of PIEZO1 - both chemically and through activating mutations - delays erythroid maturation, providing new insights into the pathophysiology of hereditary xerocytosis.
Collapse
Affiliation(s)
- Alexis Caulier
- EA4666 HEMATIM, Université Picardie Jules Verne, Amiens.,Service des Maladies du Sang, CHU Amiens, Amiens
| | | | | | | | | | - Corinne Guitton
- Service de Pédiatrie Générale, CHU Bicêtre, AP-HP, Le Kremlin-Bicêtre
| | | | - Delphine Lebon
- EA4666 HEMATIM, Université Picardie Jules Verne, Amiens.,Service des Maladies du Sang, CHU Amiens, Amiens
| | - Pascal Vong
- EA4666 HEMATIM, Université Picardie Jules Verne, Amiens
| | | | | | - Christian Rose
- Service d'Oncologie et d'Hématologie, Hôpital Saint Vincent de Paul, Lille
| | - Sandrine Gréaume
- Etablissement Français du Sang (EFS) de Normandie, Bois-Guillaume
| | - Emilie Cardon
- EA4666 HEMATIM, Université Picardie Jules Verne, Amiens
| | | | - Halima Ouadid-Ahidouch
- EA4667 Laboratoire de Physiologie Cellulaire et Moléculaire, Université Picardie Jules Verne, Amiens
| | - Jacques Rochette
- EA4666 HEMATIM, Université Picardie Jules Verne, Amiens.,Laboratoire de Génétique Moléculaire, CHU Amiens, Amiens
| | - Jean-Pierre Marolleau
- EA4666 HEMATIM, Université Picardie Jules Verne, Amiens.,Service des Maladies du Sang, CHU Amiens, Amiens
| | | | - Loïc Garçon
- EA4666 HEMATIM, Université Picardie Jules Verne, Amiens .,Service d'Hématologie Biologique, CHU Amiens.,Laboratoire de Génétique Moléculaire, CHU Amiens, Amiens
| |
Collapse
|
19
|
Cheli E, Roze J, Daouairi N, Racine J, Guy J, Ghazal K, Picard V, Girodon F. Value of combined spherocytose osmotic and EMA tests in the diagnosis of hereditary spherocytosis. Int J Lab Hematol 2019; 41:e84-e85. [DOI: 10.1111/ijlh.12976] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2018] [Revised: 12/18/2018] [Accepted: 01/04/2019] [Indexed: 11/28/2022]
Affiliation(s)
| | - Jocelyn Roze
- Laboratoire d'Hématologie; CHU Dijon; Dijon France
| | | | | | - Julien Guy
- Laboratoire d'Hématologie; CHU Dijon; Dijon France
| | | | - Véronique Picard
- Laboratoire d'Hématologie; AP-HP, CHU Bicêtre, Université Paris Sud; Le Kremlin-Bicêtre France
| | - Francois Girodon
- Laboratoire d'Hématologie; CHU Dijon; Dijon France
- UFR Santé, INSERM 1231; Dijon France
| |
Collapse
|
20
|
Picard V, Guitton C, Thuret I, Rose C, Bendelac L, Ghazal K, Aguilar-Martinez P, Badens C, Barro C, Bénéteau C, Berger C, Cathébras P, Deconinck E, Delaunay J, Durand JM, Firah N, Galactéros F, Godeau B, Jaïs X, de Jaureguiberry JP, Le Stradic C, Lifermann F, Maffre R, Morin G, Perrin J, Proulle V, Ruivard M, Toutain F, Lahary A, Garçon L. Clinical and biological features in PIEZO1-hereditary xerocytosis and Gardos channelopathy: a retrospective series of 126 patients. Haematologica 2019; 104:1554-1564. [PMID: 30655378 PMCID: PMC6669138 DOI: 10.3324/haematol.2018.205328] [Citation(s) in RCA: 69] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2018] [Accepted: 01/15/2019] [Indexed: 01/16/2023] Open
Abstract
We describe the clinical, hematologic and genetic characteristics of a retrospective series of 126 subjects from 64 families with hereditary xerocytosis. Twelve patients from six families carried a KCNN4 mutation, five had the recurrent p.Arg352His mutation and one had a new deletion at the exon 7-intron 7 junction. Forty-nine families carried a PIEZO1 mutation, which was a known recurrent mutation in only one-third of the cases and private sequence variation in others; 12 new probably pathogenic missense mutations were identified. The two dominant features leading to diagnosis were hemolysis that persisted after splenectomy and hyperferritinemia, with an inconstant correlation with liver iron content assessed by magnetic resonance imaging. PIEZO1-hereditary xerocytosis was characterized by compensated hemolysis in most cases, perinatal edema of heterogeneous severity in more than 20% of families and a major risk of post-splenectomy thrombotic events, including a high frequency of portal thrombosis. In KCNN4-related disease, the main symptoms were more severe anemia, hemolysis and iron overload, with no clear sign of red cell dehydration; therefore, this disorder would be better described as a ‘Gardos channelopathy’. These data on the largest series to date indicate that PIEZO1-hereditary xerocytosis and Gardos channelopathy are not the same disease although they share hemolysis, a high rate of iron overload and inefficient splenectomy. They demonstrate the high variability in clinical expression as well as genetic bases of PIEZO1-hereditary xerocytosis. These results will help to improve the diagnosis of hereditary xerocytosis and to provide recommendations on the clinical management in terms of splenectomy, iron overload and pregnancy follow-up.
Collapse
Affiliation(s)
- Véronique Picard
- Laboratoire d'Hématologie, Center Hospitalier Universitaire (CHU) Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre.,Université Paris Sud Paris Saclay, Faculté de Pharmacie, Chatenay Malabry
| | - Corinne Guitton
- Service de Pédiatrie Générale, CHU Bicêtre et Filière MCGRE, AP-HP, Le Kremlin-Bicêtre
| | - Isabelle Thuret
- Service de Pédiatrie, Hôpital La Timone, Aix Marseille University, Marseille
| | - Christian Rose
- Service d'Oncologie et d'Hématologie, Hôpital Saint Vincent de Paul, Lille
| | - Laurence Bendelac
- Laboratoire d'Hématologie, Center Hospitalier Universitaire (CHU) Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre
| | - Kaldoun Ghazal
- Laboratoire de Biochimie, CHU Bicêtre, AP-HP, Le Kremlin-Bicêtre
| | | | | | - Claire Barro
- Laboratoire d'Hématologie Biologique, CHU Grenoble, Grenoble
| | | | - Claire Berger
- Service d'Hématologie-Oncologie Pédiatrique, CHU, Saint-Etienne
| | | | | | | | | | - Nadia Firah
- Service de Pédiatrie, Centre Hospitaliere (CH) Pau
| | - Frédéric Galactéros
- Centre de Référence des Syndromes Drépanocytaires Majeurs, Hôpital Henri-Mondor, AP-HP, Créteil
| | - Bertrand Godeau
- Service de Médecine Interne, CHU Henri Mondor, AP-HP, Créteil
| | - Xavier Jaïs
- Service de Pneumologie, CHU Bicêtre, AP-HP, Le Kremlin-Bicêtre
| | | | | | | | - Robert Maffre
- Laboratoire d'Hématologie, Center Hospitalier Universitaire (CHU) Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre
| | | | | | - Valérie Proulle
- Laboratoire d'Hématologie, Center Hospitalier Universitaire (CHU) Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre
| | - Marc Ruivard
- Service de Médecine Interne, CHU Estaing, Clermont-Ferrand
| | | | | | - Loïc Garçon
- Laboratoire d'Hématologie, Center Hospitalier Universitaire (CHU) Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre .,Equipe d'Accueil 4666 HEMATIM Université de Picardie Jules Verne and Service d'Hématologie Biologique, CHU Amiens, France
| |
Collapse
|
21
|
Brousse V, El Hoss S, Bouazza N, Arnaud C, Bernaudin F, Pellegrino B, Guitton C, Odièvre-Montanié MH, Mames D, Brouzes C, Picard V, Nguyen-Khoa T, Pereira C, Lapouméroulie C, Pissard S, Gardner K, Menzel S, Le Van Kim C, Colin-Aronovicz Y, Buffet P, Mohandas N, Elie C, Maier-Redelsperger M, El Nemer W, de Montalembert M. Prognostic factors of disease severity in infants with sickle cell anemia: A comprehensive longitudinal cohort study. Am J Hematol 2018; 93:1411-1419. [PMID: 30132969 DOI: 10.1002/ajh.25260] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2018] [Accepted: 08/15/2018] [Indexed: 12/31/2022]
Abstract
In order to identify very early prognostic factors that can provide insights into subsequent clinical complications, we performed a comprehensive longitudinal multi-center cohort study on 57 infants with sickle cell anemia (55 SS; 2 Sβ°) during the first 2 years of life (ClinicalTrials.gov: NCT01207037). Time to first occurrence of a severe clinical event-acute splenic sequestration (ASS), vaso-occlusive (VOC) event requiring hospitalization, transfusion requirement, conditional/ abnormal cerebral velocities, or death-was used as a composite endpoint. Infants were recruited at a mean age of 4.4 ±1 months. Median follow-up was 19.4 months. During the study period, 38.6% of infants experienced ≥1 severe event: 14% ASS, 22.8% ≥ 1 VOC (median age: 13.4 and 12.8 months, respectively) and 33.3% required transfusion. Of note, 77% of the cohort was hospitalized, with febrile illness being the leading cause for admission. Univariate analysis of various biomarkers measured at enrollment showed that fetal hemoglobin (HbF) was the strongest prognostic factor of subsequent severe outcome. Other biomarkers measured at enrolment including absolute neutrophil or reticulocyte counts, expression of erythroid adhesion markers, % of dense red cells, cellular deformability or ϒ-globin genetic variants, failed to be associated with severe clinical outcome. Multivariate analysis demonstrated that higher Hb concentration and HbF level are two independent protective factors (adjusted HRs (95% CI) 0.27 (0.11-0.73) and 0.16 (0.06-0.43), respectively). These findings imply that early measurement of HbF and Hb levels can identify infants at high risk for subsequent severe complications, who might maximally benefit from early disease modifying treatments.
Collapse
Affiliation(s)
- Valentine Brousse
- Service de Pédiatrie et Maladies Infectieuses; Hôpital Universitaire Necker-Enfants Malades; Paris France
- UMR_S 1134 Biologie Intégrée du Globule Rouge; Université Sorbonne Paris Cité/Université Paris Diderot/INSERM/INTS/Laboratoire d'Excellence GR-Ex; Paris France
| | - Sara El Hoss
- UMR_S 1134 Biologie Intégrée du Globule Rouge; Université Sorbonne Paris Cité/Université Paris Diderot/INSERM/INTS/Laboratoire d'Excellence GR-Ex; Paris France
| | - Naïm Bouazza
- Unité de Recherche Clinique/Centre d'investigation clinique Paris Descartes Necker-Cochin; Assistance Publique-Hôpitaux de Paris; Paris France
- Université Paris Descartes; EA7323, Sorbonne Paris Cité; Paris France
| | - Cécile Arnaud
- Service de Pédiatrie; Centre Hospitalier Intercommunal de Créteil; Créteil France
| | - Francoise Bernaudin
- Service de Pédiatrie; Centre Hospitalier Intercommunal de Créteil; Créteil France
| | - Béatrice Pellegrino
- Service de Pediatrie; Centre Hospitalier Poissy-Saint Germain; Poissy France
| | - Corinne Guitton
- Service de Pédiatrie, Hôpital Universitaire Kremlin-Bicêtre; Le Kremlin Bicêtre France
| | | | - David Mames
- Laboratoire d'Hématologie; Hôpital Universitaire Tenon; Paris France
| | - Chantal Brouzes
- Laboratoires d'Hématologie et de Biochimie; Hôpital Universitaire Necker-Enfants Malades; Paris France
| | - Véronique Picard
- Laboratoire d'Hématologie; Hôpital Universitaire Kremlin Bicêtre; Le Kremlin Bicêtre France
| | - Thao Nguyen-Khoa
- Laboratoires d'Hématologie et de Biochimie; Hôpital Universitaire Necker-Enfants Malades; Paris France
| | - Catia Pereira
- UMR_S 1134 Biologie Intégrée du Globule Rouge; Université Sorbonne Paris Cité/Université Paris Diderot/INSERM/INTS/Laboratoire d'Excellence GR-Ex; Paris France
| | - Claudine Lapouméroulie
- UMR_S 1134 Biologie Intégrée du Globule Rouge; Université Sorbonne Paris Cité/Université Paris Diderot/INSERM/INTS/Laboratoire d'Excellence GR-Ex; Paris France
| | - Serge Pissard
- Laboratoire de Biochimie Génétique; Hôpital Universitaire Henri Mondor; Créteil France
| | - Kate Gardner
- King's College London; Division of Cancer Studies; London UK
- King's College Hospital NHS Foundation Trust; London UK
| | - Stephan Menzel
- King's College London; Division of Cancer Studies; London UK
| | - Caroline Le Van Kim
- UMR_S 1134 Biologie Intégrée du Globule Rouge; Université Sorbonne Paris Cité/Université Paris Diderot/INSERM/INTS/Laboratoire d'Excellence GR-Ex; Paris France
| | - Yves Colin-Aronovicz
- UMR_S 1134 Biologie Intégrée du Globule Rouge; Université Sorbonne Paris Cité/Université Paris Diderot/INSERM/INTS/Laboratoire d'Excellence GR-Ex; Paris France
| | - Pierre Buffet
- UMR_S 1134 Biologie Intégrée du Globule Rouge; Université Sorbonne Paris Cité/Université Paris Diderot/INSERM/INTS/Laboratoire d'Excellence GR-Ex; Paris France
| | - Narla Mohandas
- Red Cell Physiology Laboratory; New York Blood Center; New York New York
| | - Caroline Elie
- Unité de Recherche Clinique/Centre d'investigation clinique Paris Descartes Necker-Cochin; Assistance Publique-Hôpitaux de Paris; Paris France
| | | | - Wassim El Nemer
- UMR_S 1134 Biologie Intégrée du Globule Rouge; Université Sorbonne Paris Cité/Université Paris Diderot/INSERM/INTS/Laboratoire d'Excellence GR-Ex; Paris France
| | - Mariane de Montalembert
- Service de Pédiatrie et Maladies Infectieuses; Hôpital Universitaire Necker-Enfants Malades; Paris France
| |
Collapse
|
22
|
Pincez T, Guitton C, Landman-Parker J, Brousse V, Gauthier F, Da Costa L, Ghazal K, Dufillot D, Tchernia G, Picard V, Garçon L. Subtotal and total splenectomy for hereditary pyropoikilocytosis: Benefits and outcomes. Am J Hematol 2018; 93:E340-E342. [PMID: 30035308 DOI: 10.1002/ajh.25223] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2018] [Accepted: 07/16/2018] [Indexed: 11/10/2022]
Affiliation(s)
- Thomas Pincez
- Service de Pédiatrie Générale; CHU Bicêtre, AP-HP; Le Kremlin-Bicêtre France
| | - Corinne Guitton
- Service de Pédiatrie Générale; CHU Bicêtre, AP-HP; Le Kremlin-Bicêtre France
| | | | - Valentine Brousse
- Service de Pédiatrie Générale; CHU Necker-Enfants Malades, AP-HP; Paris France
| | - Frédéric Gauthier
- Service de Chirurgie Pédiatrique; CHU Bicêtre, AP-HP; Le Kremlin-Bicêtre France
| | - Lydie Da Costa
- Service d'Hématologie Biologique; CHU Robert-Debré, AP-HP; Paris France
| | - Kaldoun Ghazal
- Service de Biochimie; CHU Bicêtre, HUPS, AP-HP; Le Kremlin-Bicêtre France
| | | | - Gil Tchernia
- Service d'Hématologie Biologique; CHU Bicêtre, AP-HP; Le Kremlin-Bicêtre France
| | - Véronique Picard
- Service d'Hématologie Biologique; CHU Bicêtre, AP-HP; Le Kremlin-Bicêtre France
| | - Loïc Garçon
- Service d'Hématologie Biologique; CHU Bicêtre, AP-HP; Le Kremlin-Bicêtre France
- Service d'Hématologie Biologique; CHU Amiens; France
- Laboratoire EA HEMATIM; Université Picardie Jules-Verne; Amiens France
| |
Collapse
|
23
|
Orvain C, Da Costa L, Van Wijk R, Pissard S, Picard V, Mansour-Hendili L, Cunat S, Giansily-Blaizot M, Cartron G, Schved JF, Aguilar-Martinez P. Inherited or acquired modifiers of iron status may dramatically affect the phenotype in dehydrated hereditary stomatocytosis. Eur J Haematol 2018; 101:566-569. [DOI: 10.1111/ejh.13135] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2018] [Accepted: 06/29/2018] [Indexed: 11/29/2022]
Affiliation(s)
- Corentin Orvain
- Department of Haematology Biology; Saint Eloi Hospital; Montpellier University Hospital; Montpellier France
- Department of Blood Diseases; Angers University Hospital; Angers France
- CRCINA, INSERM; Université de Nantes; Université d'Angers; Angers France
| | - Lydie Da Costa
- Department of Biological Haematology; AP-HP; Robert Debré University Hospital; Paris France
| | - Richard Van Wijk
- Department of Clinical Chemistry and Haematology; Utrecht University Medical Center; Utrecht The Netherlands
| | - Serge Pissard
- Department of Molecular Genetics; AP-HP; Henri Mondor University Hospital; Créteil France
| | - Véronique Picard
- Laboratory of Haematology; AP-HP; Bicêtre University Hospital; Le Kremlin-Bicêtre France
| | - Lamisse Mansour-Hendili
- Department of Haematology Biology; Saint Eloi Hospital; Montpellier University Hospital; Montpellier France
- Department of Molecular Genetics; AP-HP; Henri Mondor University Hospital; Créteil France
| | - Séverine Cunat
- Department of Haematology Biology; Saint Eloi Hospital; Montpellier University Hospital; Montpellier France
| | - Muriel Giansily-Blaizot
- Department of Haematology Biology; Saint Eloi Hospital; Montpellier University Hospital; Montpellier France
| | - Guillaume Cartron
- Department of Clinical Haematology; Saint Eloi Hospital; Montpellier University Hospital; Montpellier France
| | - Jean-François Schved
- Department of Haematology Biology; Saint Eloi Hospital; Montpellier University Hospital; Montpellier France
| | - Patricia Aguilar-Martinez
- Department of Haematology Biology; Saint Eloi Hospital; Montpellier University Hospital; Montpellier France
| |
Collapse
|
24
|
Grange L, Guichard I, Berger C, Garçon L, Picard V, Cathébras P. Une nouvelle cause hématologique de surcharge martiale sévère. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.03.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
25
|
Caulier A, Rapetti-Mauss R, Guizouarn H, Picard V, Garçon L, Badens C. Primary red cell hydration disorders: Pathogenesis and diagnosis. Int J Lab Hematol 2018; 40 Suppl 1:68-73. [DOI: 10.1111/ijlh.12820] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2018] [Accepted: 03/09/2018] [Indexed: 11/26/2022]
Affiliation(s)
- A. Caulier
- EA HEMATIM; Université Picardie Jules Verne; Amiens France
| | | | - H. Guizouarn
- CNRS, INSERM, IBV; Université Côte d'Azur; Nice France
| | - V. Picard
- Faculté de Pharmacie; Université Paris Sud-Paris Saclay; Chatenay Malabry France
- AP-HP; Département d'Hématologie; Hôpital Bicêtre; Le Kremlin-Bicêtre France
| | - L. Garçon
- EA HEMATIM; Université Picardie Jules Verne; Amiens France
- Service d'Hématologie Biologique; CHU Amiens; Amiens France
| | - C. Badens
- INSERM, MMG; Aix Marseille University; Marseille France
- Laboratoire de Génétique Moléculaire; APHM; Marseille France
| |
Collapse
|
26
|
Couronné L, Tertian G, Boutron A, Picard V, Ouled-Haddou H, Hughes P, Hermine O, Préhu C, Tchernia G, Garçon L. A somatic mosaicism in the G6PD gene inducing a late onset chronic non-spherocytic hemolytic anemia. Am J Hematol 2017; 92:E153-E155. [PMID: 28395132 DOI: 10.1002/ajh.24760] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2017] [Accepted: 04/05/2017] [Indexed: 11/08/2022]
Affiliation(s)
- Lucile Couronné
- Service d'Hématologie Adultes, Hôpital Necker-Enfants Malades, INSERM UMR1163, CNRS ERL 8254, Institut Imagine, Laboratoire d'Excellence GR-Ex, Université Paris Descartes-Sorbonne Paris Cité; Paris France
| | - Gérard Tertian
- Service d'Hématologie Biologique, Hôpital Bicêtre; Le Kremlin-Bicêtre France
| | - Audrey Boutron
- Laboratoire de biochimie, Hôpital Bicêtre; Le Kremlin-Bicêtre France
| | - Véronique Picard
- Service d'Hématologie Biologique, Hôpital Bicêtre; Le Kremlin-Bicêtre France
| | | | - Patricia Hughes
- Service d'Hématologie Biologique, Hôpital Bicêtre; Le Kremlin-Bicêtre France
| | - Olivier Hermine
- Service d'Hématologie Adultes, Hôpital Necker-Enfants Malades, INSERM UMR1163, CNRS ERL 8254, Institut Imagine, Laboratoire d'Excellence GR-Ex, Université Paris Descartes-Sorbonne Paris Cité; Paris France
| | - Claude Préhu
- Laboratoire de biochimie, Hôpital Henri Mondor; Créteil France
| | - Gil Tchernia
- Service d'Hématologie Biologique, Hôpital Bicêtre; Le Kremlin-Bicêtre France
| | - Loïc Garçon
- Service d'Hématologie Biologique, Hôpital Bicêtre; Le Kremlin-Bicêtre France
- EA4666, UPJV; Amiens France
- Service d'hématologie Biologique; CHU Amiens France
| |
Collapse
|
27
|
Rapetti-Mauss R, Picard V, Guitton C, Ghazal K, Proulle V, Badens C, Soriani O, Garçon L, Guizouarn H. Red blood cell Gardos channel (KCNN4): the essential determinant of erythrocyte dehydration in hereditary xerocytosis. Haematologica 2017; 102:e415-e418. [PMID: 28619848 DOI: 10.3324/haematol.2017.171389] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
| | - Véronique Picard
- Univ Paris Sud-Paris Saclay, Faculté de pharmacie, Service d'Hématologie biologique, Hôpital Bicêtre, APHP, Le Kremlin-Bicêtre, France
| | - Corinne Guitton
- Service d'Hématologie et Rhumatologie Pédiatrique, Centre de Référence 'Maladies constitutionnelles du Globule rouge', Hôpital Bicêtre, APHP, Le Kremlin-Bicêtre, France
| | - Khaldoun Ghazal
- Service de biochimie, Hôpital Bicêtre, APHP, Le Kremlin-Bicêtre, France
| | - Valérie Proulle
- Service d'Hématologie biologique, Hôpital Bicêtre, APHP, Le Kremlin-Bicêtre, France
| | - Catherine Badens
- Aix Marseille Univ, INSERM, GMGF, Marseille, France.,APHM Département de Génétique Médicale, Hôpital de la Timone, Centre de Référence Thalassémie, Marseille, France
| | | | - Loïc Garçon
- EA4666, UPJV et Service d'Hématologie Biologique, CHU Amiens, France
| | | |
Collapse
|
28
|
Alhenc-Gelas M, Plu-Bureau G, Hugon-Rodin J, Picard V, Horellou MH. Thrombotic risk according to SERPINC1 genotype in a large cohort of subjects with antithrombin inherited deficiency. Thromb Haemost 2017; 117:1040-1051. [PMID: 28300866 DOI: 10.1160/th16-08-0635] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2016] [Accepted: 02/23/2017] [Indexed: 12/24/2022]
Abstract
Inherited quantitative (type I) or qualitative (type II) antithrombin deficiency (ATD) due to mutations in the SERPINC1 gene is a well-known risk factor for venous thromboembolism. ATD may also increase risk for arterial thrombosis. Few studies have investigated risk for thrombosis according to mutations. We addressed this topic in a large retrospective cohort study of 540 heterozygous carriers of SERPINC1 mutations and compared risk for first venous or arterial thrombosis associated with carrying of different type II or type I mutations. No clear difference in risk for first venous thrombotic event was observed among type I (missense or null), type IIRS or type IIPE mutation carriers except for a few variants that displayed lower risk [all events, adjusted relative risk: Cambridge II: 0.42 (95 %CI 0.25-0.70), Dublin: 0.35 (95 %CI 0.13-0.99)]. IIHBS mutation carrying was associated with a clearly lower risk than type I mutation carrying [0.28 (95 %CI 0.20-0.40)]. These differences in risk were observed for both all venous thrombotic events and pulmonary embolism associated with deep venous thrombosis. The HBS group was also heterogeneous, with AT Budapest 3 carriers displaying a non-significantly different risk [0.61 (95 %CI 0.31-1.20)] compared to type I mutation carriers. We also studied risk for arterial thrombosis and found no significant influence of mutation type. Altogether, our findings suggest a place for SERPINC1 genotyping in the diagnosis of ATD.
Collapse
Affiliation(s)
- Martine Alhenc-Gelas
- M. Alhenc-Gelas, Laboratoire d'Hématologie, HEGP, 20 Rue Leblanc, 75015 Paris, France, Tel: +33 156093901, Fax: +33 156093393, E-mail:
| | | | | | | | | | | |
Collapse
|
29
|
Abstract
Non-immune hemolytic anemia (NIHA) is characterized by positive routine hemolytic tests but negative anti-human immunoglobulin (Coombs) test. Hereditary non-immune hemolysis includes disorders of erythrocytic enzymes, membrane, hemoglobin (qualitative and quantitative disorders), as well as the rare hereditary forms of thrombotic microangiopathies. Acquired NIHA includes paroxysmal nocturnal hemolysis (PNH), infections, drug and metal intoxications with as a target red blood cells or endothelium of capillaries, the rare acquired forms of thalassemia or erythrocytic membrane disorders, and hemolysis secondary to a dysfunctioning artificial (prosthetic) cardiac valve. Identification of the specific cause of NIHA is sometimes difficult and requires not only a good knowledge of this entity but mainly a qualified specialized hematologic laboratory. An algorithm to be used in every new patient consulting for NIHA is proposed in the last part of this article.
Collapse
Affiliation(s)
- Photis Beris
- Service d'Hématologie, Département de Médecine Interne, Centre Médical Universitaire Genève Suisse, Geneva, Switzerland; Département d'hématologie, Laboratoire central Unilabs, Coppet, Switzerland.
| | - Véronique Picard
- Service d'Hématologie biologique, Hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre, France; Laboratoire d'Hématologie, Faculté de Pharmacie, Université Paris-Sud, France
| |
Collapse
|
30
|
Aumont C, Driss F, Lazure T, Picard V, Creidy R, De Botton S, Saada V, Lambotte O, Bilhou-Nabera C, Tertian G, Michot JM. Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia. Am J Hematol 2015; 90:E131-2. [PMID: 25801602 DOI: 10.1002/ajh.24010] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2014] [Revised: 03/02/2015] [Accepted: 03/11/2015] [Indexed: 11/07/2022]
Affiliation(s)
- Cédric Aumont
- Service D'hématologie Biologique, Assistance Publique-Hôpitaux De Paris; Hôpital Universitaire Bicêtre; Le Kremlin Bicêtre Cedex; France
| | - Françoise Driss
- Service De Médecine Interne Et Immunologie Clinique, Assistance Publique-Hôpitaux De Paris; Hôpital Universitaire Bicêtre; Le Kremlin Bicêtre Cedex France
| | - Thierry Lazure
- Service D'anatomie Pathologique, Assistance Publique-Hôpitaux De Paris; Hôpital Universitaire Bicêtre, Le Kremlin Bicêtre; Cedex; France
| | - Véronique Picard
- Service D'hématologie Biologique, Assistance Publique-Hôpitaux De Paris; Hôpital Universitaire Bicêtre; Le Kremlin Bicêtre Cedex; France
| | - Rita Creidy
- Service D'hématologie Biologique, Assistance Publique-Hôpitaux De Paris; Hôpital Universitaire Bicêtre; Le Kremlin Bicêtre Cedex; France
| | - Stéphane De Botton
- Service D'hématologie; Gustave Roussy; Villejuif Cedex France
- Université Paris Sud 11; Le Kremlin-Bicêtre; Cedex France
| | - Véronique Saada
- Laboratoire D'hématologie; Gustave; Roussy Villejuif Cedex France
| | - Olivier Lambotte
- Service De Médecine Interne Et Immunologie Clinique, Assistance Publique-Hôpitaux De Paris; Hôpital Universitaire Bicêtre; Le Kremlin Bicêtre Cedex France
- Université Paris Sud 11; Le Kremlin-Bicêtre; Cedex France
| | - Chrystèle Bilhou-Nabera
- Service D'hématologie Biologique, Assistance Publique-Hôpitaux De Paris; Hôpital Universitaire Bicêtre; Le Kremlin Bicêtre Cedex; France
| | - Gérard Tertian
- Service D'hématologie Biologique, Assistance Publique-Hôpitaux De Paris; Hôpital Universitaire Bicêtre; Le Kremlin Bicêtre Cedex; France
- Université Paris Sud 11; Le Kremlin-Bicêtre; Cedex France
| | - Jean-Marie Michot
- Service De Médecine Interne Et Immunologie Clinique, Assistance Publique-Hôpitaux De Paris; Hôpital Universitaire Bicêtre; Le Kremlin Bicêtre Cedex France
- Service D'hématologie; Gustave Roussy; Villejuif Cedex France
| |
Collapse
|
31
|
El Nabouch M, Rakotoharinandrasana I, Ndayikeza A, Picard V, Kayemba-Kay's S. Infantile pyknocytosis, a rare cause of hemolytic anemia in newborns: report of two cases in twin girls and literature overview. Clin Case Rep 2015; 3:535-8. [PMID: 26273436 PMCID: PMC4527790 DOI: 10.1002/ccr3.288] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2014] [Revised: 01/11/2015] [Accepted: 01/20/2015] [Indexed: 12/23/2022] Open
Abstract
Infantile pyknocytosis is a rare cause of neonatal jaundice and hemolytic anemia. We report on two cases in twin girls that were diagnosed on peripheral blood smear reading. Pyknocytosis should be considered in cases of early unexplained severe hemolytic anemia, and systematic peripheral smear review performed. Its management consists of phototherapy and RBC transfusion.
Collapse
Affiliation(s)
- Mohamad El Nabouch
- Service de Pédiatrie & Médecine Néonatale, Centre Hospitalier de Dreux Dreux, France
| | | | - Alexis Ndayikeza
- Service de Pédiatrie & Médecine Néonatale, Centre Hospitalier de Dreux Dreux, France
| | - Véronique Picard
- Laboratoires d'Hématologie Pédiatrique, CHU de Kremlin Bicêtre, Assistance Publique Hôpitaux de Paris Paris, France
| | - Simon Kayemba-Kay's
- Service de Pédiatrie & Médecine Néonatale, Centre Hospitalier de Dreux Dreux, France ; Unité de Recherche Clinique 28 (URC28), Centre Hospitalier de Dreux Dreux, France
| |
Collapse
|
32
|
King MJ, Garçon L, Hoyer JD, Iolascon A, Picard V, Stewart G, Bianchi P, Lee SH, Zanella A. ICSH guidelines for the laboratory diagnosis of nonimmune hereditary red cell membrane disorders. Int J Lab Hematol 2015; 37:304-25. [PMID: 25790109 DOI: 10.1111/ijlh.12335] [Citation(s) in RCA: 102] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2014] [Accepted: 01/22/2015] [Indexed: 01/19/2023]
Abstract
INTRODUCTION Hereditary spherocytosis (HS), hereditary elliptocytosis (HE), and hereditary stomatocytosis (HSt) are inherited red cell disorders caused by defects in various membrane proteins. The heterogeneous clinical presentation, biochemical and genetic abnormalities in HS and HE have been well documented. The need to raise the awareness of HSt, albeit its much lower prevalence than HS, is due to the undesirable outcome of splenectomy in these patients. METHODS The scope of this guideline is to identify the characteristic clinical features, the red cell parameters (including red cell morphology) for these red cell disorders associated, respectively, with defective cytoskeleton (HS and HE) and abnormal cation permeability in the lipid bilayer (HSt) of the red cell. The current screening tests for HS are described, and their limitations are highlighted. RESULTS An appropriate diagnosis can often be made when the screening test result(s) is reviewed together with the patient's clinical/family history, blood count results, reticulocyte count, red cell morphology, and chemistry results. SDS-polyacrylamide gel electrophoresis of erythrocyte membrane proteins, monovalent cation flux measurement, and molecular analysis of membrane protein genes are specialist tests for further investigation. CONCLUSION Specialist tests provide additional evidence in supporting the diagnosis and that will facilitate the management of the patient. In the case of a patient's clinical phenotype being more severe than the affected members within the immediate family, molecular testing of all family members is useful for confirming the diagnosis and allows an insight into the molecular basis of the abnormality such as a recessive mode of inheritance or a de novo mutation.
Collapse
Affiliation(s)
- M-J King
- Membrane Biochemistry, NHS Blood and Transplant, Bristol, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Haliloglu G, Maluenda J, Sayinbatur B, Aumont C, Temucin C, Tavil B, Cetin M, Oguz KK, Gut I, Picard V, Melki J, Topaloglu H. Early-onset chronic axonal neuropathy, strokes, and hemolysis: Inherited CD59 deficiency. Neurology 2015; 84:1220-4. [DOI: 10.1212/wnl.0000000000001391] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
34
|
Limperger V, Franke A, Kenet G, Holzhauer S, Picard V, Junker R, Heller C, Gille C, Manner D, Kurnik K, Knoefler R, Mesters R, Halimeh S, Nowak-Göttl U. Clinical and laboratory characteristics of paediatric and adolescent index cases with venous thromboembolism and antithrombin deficiency. An observational multicentre cohort study. Thromb Haemost 2014; 112:478-85. [PMID: 24966143 DOI: 10.1160/th14-02-0149] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2014] [Accepted: 04/02/2014] [Indexed: 11/05/2022]
Abstract
Venous thromboembolism [TE] is a multifactorial disease and antithrombin deficiency [ATD] constitutes a major risk factor. In the present study the prevalence of ATD and the clinical presentation at TE onset in a cohort of paediatric index cases are reported. In 319 unselected paediatric patients (0.1-18 years) from 313 families, recruited between July 1996 and December 2013, a comprehensive thrombophilia screening was performed along with recording of anamnestic data. 21 of 319 paediatric patients (6.6%), corresponding to 16 of 313 families (5.1%), were AT-deficient with confirmed underlying AT gene mutations. Mean age at first TE onset was 14 years (range 0.1 to 17). Thrombotic locations were renal veins (n=2), cerebral veins (n=5), deep veins (DVT) of the leg (n=9), DVT & pulmonary embolism (n=4) and pelvic veins (n=1). ATD co-occurred with the factor-V-Leiden mutation in one and the prothrombin G20210A mutation in two children. In 57.2% of patients a concomitant risk factor for TE was identified, whereas 42.8% of patients developed TE spontaneously. A second TE event within primarily healthy siblings occurred in three of 313 families and a third event among siblings was observed in one family. In an unselected cohort of paediatric patients with symptomatic TE, the prevalence of ATD adjusted for family status was 5.1%. Given its clinical implication for patients and family members, thrombophilia testing should be performed and the benefit of medical or educational interventions should be evaluated in this high risk population.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | - U Nowak-Göttl
- Ulrike Nowak-Göttl, Center of Thrombosis & Hemostasis, Institute of Clinical Chemistry, Univ. Hospital Kiel, Arnold-Heller-Str. 3, Building 17, 24105 Kiel, Germany, E-mail:
| |
Collapse
|
35
|
Mayeur-Rousse C, Gentil M, Botton J, Thibaut MF, Guitton C, Picard V. Testing for hereditary spherocytosis: a French experience. Haematologica 2013. [PMID: 23204481 DOI: 10.3324/haematol.2012.074070] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
36
|
Fazavana J, Bianchini EP, Saller F, Smadja C, Picard V, Taverna M, Borgel D. A chemically-modified inactive antithrombin as a potent antagonist of fondaparinux and heparin anticoagulant activity. J Thromb Haemost 2013; 11:1128-36. [PMID: 23581397 DOI: 10.1111/jth.12249] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2012] [Indexed: 11/30/2022]
Abstract
BACKGROUND Heparin and its analogs, mediating their anticoagulant activity through antithrombin (AT) activation, remain largely used for the preventive and curative treatment of thrombosis. The major adverse reaction of these drugs is the bleeding risk associated with overdose. Unfractionnated heparin (UFH) can be efficiently and rapidly neutralized by protamine sulfate, but this reversal partially neutralizes low-molecular-weight heparin (LMWH) and is inefficient in reversing fondaparinux. To secure administration of AT-mediated anticoagulants and counteract bleeding disorders, we previously designed a recombinant inactive AT as an antidote to heparin derivatives. OBJECTIVES To get around the limited production level of recombinant AT, we propose in this study an alternative strategy to produce a chemically modified inactive AT, exhibiting increased heparin affinity, as an antagonist of heparin analogs. METHODS Plasma-derived AT was chemically modified with 2,3 butanedione, a diketone known to specifically react with the arginine side chain. The chemical reaction was conducted in the presence of heparin to preserve basic residues within the heparin binding site from modifications. RESULTS AT treated by butanedione and selected for its high heparin affinity (AT-BD) was indeed modified on reactive Arg393 and thus exhibited decreased anticoagulant activity and increased heparin affinity. AT-BD was able to neutralize anticoagulant activity of heparin derivatives in vitro and in vivo and was devoid of intrinsic anticoagulant activity, as assessed by activated partial thromboplastin time assay. CONCLUSIONS AT-BD appears to be as efficient as protamine to neutralize UFH in vivo but could be more largely used because it also reverses fondaparinux and LMWH.
Collapse
Affiliation(s)
- J Fazavana
- Laboratoire d'Hématologie, University Paris-Sud-XI, Châtenay-Malabry Cedex, France
| | | | | | | | | | | | | |
Collapse
|
37
|
Cambot M, Mazurier C, Canoui-Poitrine F, Hebert N, Picot J, Clay D, Picard V, Ripoche P, Douay L, Dubart-Kupperschmitt A, Cartron JP. In vitro generated Rh(null) red cells recapitulate the in vivo deficiency: a model for rare blood group phenotypes and erythroid membrane disorders. Am J Hematol 2013; 88:343-9. [PMID: 23417980 DOI: 10.1002/ajh.23414] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2013] [Revised: 02/08/2013] [Accepted: 02/09/2013] [Indexed: 11/08/2022]
Abstract
Lentiviral modification combined with ex vivo erythroid differentiation was used to stably inhibit RhAG expression, a critical component of the Rh(rhesus) membrane complex defective in the Rh(null) syndrome. The cultured red cells generated recapitulate the major alterations of native Rh(null) cells regarding antigen expression, membrane deformability, and gas transport function, providing the proof of principle for their use as model of Rh(null) syndrome and to investigate Rh complex biogenesis in human primary erythroid cells. Using this model, we were able to reveal for the first time that RhAG extinction alone is sufficient to explain ICAM-4 and CD47 loss observed on native Rh(null) RBCs. Together with the effects of RhAG forced expression in Rh(null) progenitors, this strongly strengthens the hypothesis that RhAG is critical to Rh complex formation. The strategy is also promising for diagnosis purpose in order to overcome the supply from rare blood donors and is applicable to other erythroid defects and rare phenotypes, providing models to dissect membrane biogenesis of multicomplex proteins in erythroid cells, with potential clinical applications in transfusion medicine.
Collapse
Affiliation(s)
- Marie Cambot
- Institut National de la Transfusion Sanguine (INTS); 75015; Paris; France
| | | | | | | | - Julien Picot
- Institut National de la Transfusion Sanguine (INTS); 75015; Paris; France
| | | | - Véronique Picard
- Laboratoire d'Hématologie; Centre Hospitalier Universitaire de Bicêtre; 94275; Le Kremlin-Bicêtre; France
| | - Pierre Ripoche
- Institut National de la Transfusion Sanguine (INTS); 75015; Paris; France
| | | | | | | |
Collapse
|
38
|
Beneteau C, Thierry G, Blesson S, Le Vaillant C, Picard V, Béné MC, Eveillard M, Le Caignec C. Recurrent mutation in the PIEZO1 gene in two families of hereditary xerocytosis with fetal hydrops. Clin Genet 2013; 85:293-5. [PMID: 23581886 DOI: 10.1111/cge.12147] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2013] [Revised: 03/14/2013] [Accepted: 03/15/2013] [Indexed: 11/29/2022]
Affiliation(s)
- C Beneteau
- CHU Nantes, Service de Génétique Médicale, Nantes, France
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Albuisson J, Murthy SE, Bandell M, Coste B, Louis-Dit-Picard H, Mathur J, Fénéant-Thibault M, Tertian G, de Jaureguiberry JP, Syfuss PY, Cahalan S, Garçon L, Toutain F, Simon Rohrlich P, Delaunay J, Picard V, Jeunemaitre X, Patapoutian A. Dehydrated hereditary stomatocytosis linked to gain-of-function mutations in mechanically activated PIEZO1 ion channels. Nat Commun 2013; 4:1884. [PMID: 23695678 PMCID: PMC3674779 DOI: 10.1038/ncomms2899] [Citation(s) in RCA: 243] [Impact Index Per Article: 22.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2013] [Accepted: 04/18/2013] [Indexed: 02/06/2023] Open
Abstract
Dehydrated hereditary stomatocytosis is a genetic condition with defective red blood cell membrane properties that causes an imbalance in intracellular cation concentrations. Recently, two missense mutations in the mechanically activated PIEZO1 (FAM38A) ion channel were associated with dehydrated hereditary stomatocytosis. However, it is not known how these mutations affect PIEZO1 function. Here, by combining linkage analysis and whole-exome sequencing in a large pedigree and Sanger sequencing in two additional kindreds and 11 unrelated dehydrated hereditary stomatocytosis cases, we identify three novel missense mutations and one recurrent duplication in PIEZO1, demonstrating that it is the major gene for dehydrated hereditary stomatocytosis. All the dehydrated hereditary stomatocytosis-associated mutations locate at C-terminal half of PIEZO1. Remarkably, we find that all PIEZO1 mutations give rise to mechanically activated currents that inactivate more slowly than wild-type currents. This gain-of-function PIEZO1 phenotype provides insight that helps to explain the increased permeability of cations in red blood cells of dehydrated hereditary stomatocytosis patients. Our findings also suggest a new role for mechanotransduction in red blood cell biology and pathophysiology.
Collapse
|
40
|
|
41
|
Bonhomme-Faivre L, Picard V, Saliba F, Abbara C, Fodil M, Chaunoy M, Farinotti R. Effect of the ABCB1 3435C>T polymorphism on tacrolimus concentrations and dosage requirements in liver transplant recipients. Am J Health Syst Pharm 2009; 66:1645-51. [PMID: 19729569 DOI: 10.2146/ajhp080396] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
PURPOSE The effect of ABCB1 3435C>T on tacrolimus concentrations in liver transplant recipients was studied. Tacrolimus is a substrate for P-glycoprotein, the product of the ABCB1 gene. To determine whether the ABCB1 single-nucleotide polymorphism (SNP) 3435C>T was associated with variation in the tacrolimus concentration:dose ratio (C:D) in 42 liver transplant recipients during three months after transplantation. METHODS Forty-two Caucasian patients who underwent an orthotopic liver transplantation from cadaveric donors received a basic immunosuppressive regimen containing tacrolimus and corticosteroids; mycophenolate mofetil was added in 18 cases. The SNP 3435C>T in exon 26 was investigated by MboI restriction-enzyme digestion, leading to the identification of CC, TT, or CT status at nucleotide 3435. Results obtained for the three genotypes were compared for each of three values: daily weight-adjusted tacrolimus dose, blood trough tacrolimus concentration, and C:D. RESULTS The wild-type genotype (3435CC) was observed in 10 patients (24%); 23 patients (55%) were heterozygous (3435CT) and 9 patients (21%) were homozygous for the mutation (3435TT). One to three days after liver transplantation, the mean +/- S.D. C:D was significantly higher in subjects homozygous for the mutation compared with subjects with the wild-type allele (236 +/- 119 ng . kg/mL . mg versus 104 +/- 74 ng . kg/mL . mg, respectively; p = 0.0167). Subjects with the heterozygous allele had an intermediate mean +/- S.D. C:D (131 +/- 108 ng . kg/mL . mg). One or three months after transplantation, no significant difference in the tacrolimus C:D was evident among the three groups. CONCLUSION The ABCB1 3435C>T polymorphism influenced the tacrolimus C:D in the first days after liver transplantation.
Collapse
|
42
|
Paule B, Castagne V, Picard V, Saffroy R, Adam R, Guettier C, Farinotti R, Bonhomme-Faivre L. MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. Med Oncol 2009; 27:1066-72. [PMID: 19862647 DOI: 10.1007/s12032-009-9336-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2009] [Accepted: 10/06/2009] [Indexed: 01/17/2023]
Abstract
The aim of the study was to evaluate the influence of the MDR1 C3435T polymorphism on the therapeutic response in 23 patients treated with cetuximab plus irinotecan for irinotecan refractory liver metastatic colorectal cancer considering their KRAS status. Indeed, irinotecan and its active metabolite (SN-38) are both substrates of P-glycoprotein (P-gp) encoded by MDR1. Patients received cetuximab and irinotecan up to progression. The overall survival was 55% at 10 months. Overall, four patients had an undetermined KRAS status and two patients with mutated KRAS were in progression disease. The response to treatment was observed after 3 months among the 17 wild-type KRAS patients. Two patients presented a progressive disease (1 TT and 1 CT), eight patients had a stable disease (5 CC and 3CT) and five patients had a partial response (3 CC and 2 CT). Importantly, 2 patients (2 TT) were in complete response and still alive 5 years after starting the treatment, which suggests that the combination of wild-type KRAS and MDR1 3435 TT may be a factor of good prognosis. These results suggest that EGFR inhibition by cetuximab may overcome this irinotecan resistance by abrogating drug efflux depending on MDR1 3435 polymorphism. Among patients resistant to irinotecan, it is still possible to use the association of cetuximab plus irinotecan to obtain a complete resection of hepatic metastases that is necessary to improve their survival.
Collapse
Affiliation(s)
- Bernard Paule
- Centre Hépatobiliaire, Department of Pharmacy-Pharmacology, Paul Brousse University Hospital, AP-HP, 12-14, avenue Paul Vaillant-Couturier, Villejuif, France
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Benyamina A, Bonhomme-Faivre L, Picard V, Sabbagh A, Richard D, Blecha L, Rahioui H, Karila L, Lukasiewicz M, Farinotti R, Picard V, Marill C, Reynaud M. Association between ABCB1 C3435T polymorphism and increased risk of cannabis dependence. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:1270-4. [PMID: 19625010 DOI: 10.1016/j.pnpbp.2009.07.016] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/14/2009] [Revised: 07/15/2009] [Accepted: 07/15/2009] [Indexed: 10/20/2022]
Abstract
Prolonged cannabis use has a significant impact on health and well-being. Genetic factors are known to influence cannabis dependence, but few specific genetic markers have been identified. ABCB1 polymorphisms are known to modify drug pharmacokinetics but have yet to be studied for their role in generating and maintaining cannabis dependence. The objective of this study is to determine if ABCB1 C3435T polymorphism may represent an independent genetic marker for cannabis dependence risk. An open bi-centric association study was conducted in two French Addiction Centres. Caucasian patients diagnosed with isolated cannabis dependence were compared with healthy age-matched controls for socio-demographic, clinical and genetic data using chi-square test, Fisher's exact test, or Mann-Whitney U test. Independent association between ABCB1 C3435T SNP marker and cannabis dependence was evaluated using multiple logistic regression analysis. Versus controls (n=40), patients with cannabis dependence (n=40) had a significantly higher 3435C allele frequency (62.5% versus 43.8% respectively, P=0.017) and CC genotype (50% versus 20%, P=0.005, OR=4.00 [1.50-10.60]). Multiple logistic regression analysis of the C3435T SNP and variables identified in univariate analyses indicated that the CC genotype was independently associated with cannabis dependence (P=0.045, OR=6.61 [1.05-46.58]). This is the first time a significant specific genetic marker has been shown in cannabis dependence. ABCB1 polymorphisms may alter Delta9THC distribution, its psychoactive effects and individual vulnerability to dependence. These results pave the way to a new pharmacogenetic hypothesis in cannabis dependence.
Collapse
|
44
|
Picard V, Présot I, Scarabin PY, Aiach M, Emmerich J, Alhenc-Gelas M. Antithrombin Cambridge II (A384S): prevalence in patients of the Paris Thrombosis Study (PATHROS). Blood 2007; 110:2777-8. [PMID: 17881648 DOI: 10.1182/blood-2007-05-091835] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Abstract
The coagulation system is governed by a subtle balance between clotting activators and inhibitors. Many genes can contribute to the overall phenotype, and polymorphisms may act to up regulate or down regulate the generation of thrombin, the coagulation-key enzyme. An increase in coagulation factor (gain function) or/and a decrease in coagulation inhibitors (loss of function) may favor venous thromboembolism (VTE). It has been observed since a long time that VTE may be a familial disease, but it was only in 1965 that Egeberg published the first case of inherited antithrombin (AT) deficiency. This was followed by similar reports of protein C (PC) and protein S (PS) deficiencies. Hereditary thrombophilia was thus initially considered as a rare monogenic disorder with incomplete penetrance. AT, PC and PS deficiencies are due to multiple and mostly private mutations of the corresponding genes. Most patients are heterozygous and experience VTE at adult age. Homozygosity associated with severe thrombosis at birth has been observed in newborns with undetectable PC or PS concentrations. The discovery of factor (F) V Leiden and F2 g.20210 G>A, two gain of function mutations, challenged the view of thrombophilia as a rare monogenic disorder. FV Leiden and F2 g.20210 G>A are due to a founder effect and affect populations of European descent with frequencies at 5% and 3% respectively. These two mutations are moderate of risk factor for thrombosis and paved the way for gene-gene and gene-environment interactions. Patients carrying more than one genetic risk factor are at higher risk to develop VTE. The exposition to acquired risk factors such as estrogen based oral contraception may also have a synergistic effect favoring thrombosis in patients with FV Leiden or other genetic risk factors.
Collapse
Affiliation(s)
- Martine Aiach
- Service d'Hématologie Biologique, Hôpital Européen Georges Pompidou, 20, Rue Leblanc, 75908 Paris Cedex 15, France.
| | | | | | | | | | | |
Collapse
|
46
|
Picard V, Nowak-Göttl U, Biron-Andreani C, Fouassier M, Frere C, Goualt-Heilman M, de Maistre E, Regina S, Rugeri L, Ternisien C, Trichet C, Vergnes C, Aiach M, Alhenc-Gelas M. Erratum: Molecular bases of antithrombin deficiency: twenty-two novel mutations in the antithrombin gene. Hum Mutat 2006. [DOI: 10.1002/humu.9468] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
47
|
Vautier S, Lacomblez L, Chacun H, Picard V, Gimenez F, Farinotti R, Fernandez C. Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood–brain barrier in the mouse. Eur J Pharm Sci 2006; 27:167-74. [PMID: 16263252 DOI: 10.1016/j.ejps.2005.09.009] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2005] [Revised: 07/20/2005] [Accepted: 09/22/2005] [Indexed: 11/26/2022]
Abstract
Bromocriptin (BCT) is a dopaminergic receptor agonist, poorly transported through the blood-brain barrier (BBB) and responsible for central side effects. Interactions between BCT and the efflux protein, P-glycoprotein (Pgp), have been described in vitro but nothing is known in vivo nor at the BBB level. At the BBB, in vivo, we investigated BCT as (i) a Pgp substrate by comparing the brain uptake in CF1 mdr1a(-/-) and mdr1a(+/+) mice with or without inhibitors of Pgp (valspodar, elacridar); (ii) a Pgp inducer by looking at the effect of repeated doses of BCT on cerebral uptake of digoxin and comparing it to the effect of dexamethasone and rifampicin; (iii) a Pgp inhibitor by determining the effect of a single dose of BCT on cerebral uptake of digoxin and comparing it to the effect of valspodar. CF1 mdr1a(-/-) mice showed much higher brain uptake of BCT than CF1 mdr1a(+/+) mice and brain uptake of BCT was higher in CF1 mdr1a(+/+) mice pre-treated with valspodar or elacridar indicating that BCT is a Pgp substrate at the BBB level. Brain uptake of digoxin was not modified in CF1 mdr1a(+/+) mice pre-treated with a single dose or repeated doses of BCT, indicating that BCT is neither a Pgp inductor nor a Pgp inhibitor at the BBB in the chosen experimental setting. In vivo, at the mouse BBB level and in our experimental conditions, bromocriptin is a Pgp substrate but is not a Pgp modulator.
Collapse
Affiliation(s)
- Sarah Vautier
- EA 2706, Département de Pharmacie Clinique, Faculté de Pharmacie, 5 rue Jean Baptiste Clément, 92296 Châtenay-Malabry, France
| | | | | | | | | | | | | |
Collapse
|
48
|
Picard V, Nowak-Göttl U, Biron-Andreani C, Fouassier M, Frere C, Goualt-Heilman M, de Maistre E, Regina S, Rugeri L, Ternisien C, Trichet C, Vergnes C, Aiach M, Alhenc-Gelas M. Molecular bases of antithrombin deficiency: twenty-two novel mutations in the antithrombin gene. Hum Mutat 2006; 27:600. [PMID: 16705712 DOI: 10.1002/humu.9425] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Antithrombin (AT) is a major physiological inhibitor of hemostasis. We report 22 novel antithrombin gene (SERPINC1) mutations associated with antithrombin deficiency in 17 French and five German families. They were all present at the heterozygous state. Nine missense mutations accounted for type I deficiency, defined by equally low antithrombin activity and antigen level. Most of them (7/9) affected highly conserved serpin residues and were associated with venous thrombosis occurring at a young age (before age 32). One splice site, one nonsense mutation, three small deletions and one insertion were also identified as a cause for type I antithrombin deficiency. Seven other missense mutations were identified in type II or unclassified AT deficiency; g.5270C>T (p.T147I, T115I) and g.5281A>T (p.I151F, I119F) change residues in the heparin binding region, g.13267C>G (p.P439A, P407A) and g.13271T>C (p.F440S, F408S) affect amino acids in the pleiotropic region, g.2372G>A (p.G25D, G-8D) changes a signal peptide amino acid, g.2456G>C (p.C53S, C21S) affects one of the three disulfide bonds of the protein, and g.7585A>T (p.M347K, M315K) changes a nonconserved residue on strand 2C.
Collapse
Affiliation(s)
- Véronique Picard
- Service d'hématologie Biologique A, Hôpital Européen Georges Pompidou, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Fradet Y, Picard V, Bergeron A, LaRue H. Cancer-testis antigen expression in bladder cancer. Prog Urol 2005; 15:1303-13. [PMID: 16734221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/09/2023]
Abstract
PURPOSE To evaluate the potential of cCancer-t/Testis antigens (CTAs) as targets for immunotherapy of bladder cancer, we evaluated the expression of 9 CTA genes or families of genes in normal urothelia, bladder tumours and bladder cancer human bladder tissuescell lines. As expression of most CTAs is controlled by epigenetic mechanisms, we also evaluated the effect of the DNA methylase inhibitor 5-aza-2'-deoxycytidine (5-AZA-DC), and/or theand histone deacetylase inhibitors Trichostatin A (TSA) on their expression in bladder cancer cell lines. MATERIAL AND METHODS Expression of NY-ESO-1/LAGE-1, MAGE-A, MAGE-C1, BAGE, HOM-TES-85, SCP-1, SSX-1, SSX-2 and SSX-4 was analyzed by semi-quantitative RT-PCR and Western blotting on 10 normal urothelia, 23 24 superficial and 223 invasive tumours and on 10 cell lines treated with 5-aza-2'-deoxycytidine (5-AZA-DC) and/or Trichostatin A (TSA). RESULTS Expression of all CTA genes could be observed in at least 1 tumour except for HOM-TES-85 for which mRNA was never detected. MAGE-A, BAGE and NY-ESO-1/LAGE-1 mRNAs were the most frequently detected, respectively in 5677%, 212% and 89% of superficial and in 6461%, 4139% and 276% of invasive tumours. With the exception of MAGE-A, CTA transcripts were rarely detected in the cell lines. However, expression of all CTA genes, except SCP-1, could be induced at various levels by the drugs and 5-AZA-DC was a much more potent inducer than TSA. CONCLUSION These data suggest that immunotherapy of bladder cancer could target CTAs, especially those expressed at higher frequency such as MAGE-A, BAGE and NY-ESO-1/LAGE-1. Moreover, their induction by chemotherapeutic agents such as 5-AZA-DC, provides a potential pretreatment aimed at inducing the immunogenicity of the tumours.
Collapse
Affiliation(s)
- Yves Fradet
- Laboratoire d'Uro-Oncologie Expérimentale, Centre de recherche en cancérologie de l'Université Laval, CHUQ-L'Hôtel-Dieu de Québec, Canada
| | | | | | | |
Collapse
|
50
|
Picard V, Bauters A, Khairy M, Ochat N, Jude B, Aiach M, Alhenc-Gelas M. Conformational Asn187Asp/Lys antithrombin variants and thrombosis. Clinical and biological features in 13 new heterozygotes. Thromb Haemost 2005; 93:57-62. [PMID: 15630491 DOI: 10.1160/th04-08-0477] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Antithrombin Rouen VI (N187D) is a rare conformational thermolabile variant. The unique symptomatic carrier reported in the literature developed 3 thrombotic events during pregnancy, in each case in a context of pyrexial infection. In fresh plasma, antithrombin activity and antigen level were normal but in vitro experiments demonstrated the presence of a thermolabile variant, suggesting that fever could be a trigger for thrombosis in N187D carriers. The RouenVI variant was further found in two asymptomatic brothers. In these subjects, it was associated with normal antigen level but reduced activity. In order to better delineate the functional and clinical consequences of the N187 variants, we have studied a series of seven subjects from two distinct families heterozygous for the Rouen VI mutation. Antithrombin levels were normal or borderline in these patients. Thermostability of plasma antithrombin was normal. We have also studied six subjects heterozygous for a new mutation, 6462C>G,which results in an asparagine to lysine substitution at residue 187. In these patients, the N187K mutation is associated with a clear type II deficiency and decreased thermostability of the plasma protein has been demonstrated. That the N187D mutation has milder consequences on plasma antithrombin activity than the N187K mutation is in agreement with structural predictions. About 50% of the N187 carriers studied have suffered venous thrombotic events, strongly suggesting that both mutations are risk factors for thrombosis, but none occurred during pyrexial infections.
Collapse
Affiliation(s)
- Véronique Picard
- Service d'Hématologie Biologique A, Hôpital Européen Georges Pompidou 20 rue Leblanc, 75908 Paris cedex 15, France.
| | | | | | | | | | | | | |
Collapse
|